

CS Investment Funds 5

Investment Company with Variable Capital under Luxembourg law - R.C.S. Luxembourg B 81 507

Unaudited Semi-Annual Report at 31.03.2016

Table of Contents Page 2

Management and Administration	3
Consolidated Report	5
Notes	7
Report by subfund	
Credit Suisse (Lux) Asia Consumer Equity Fund	10
Credit Suisse (Lux) Asia Pacific ILC Equity Fund	14
Credit Suisse (Lux) Asian Equity Dividend Plus Fund	19
Credit Suisse (Lux) Europe ILC Equity Fund	23
Credit Suisse (Lux) Global Biotech Innovators Equity Fund	27
Credit Suisse (Lux) Global Energy Winners Equity Fund	31
Credit Suisse (Lux) Global Small and Mid Cap Emerging Markets ILC Equity Fund	35
Credit Suisse (Lux) Infrastructure Equity Fund	41
Credit Suisse (Lux) Pussian Equity Fund	ΛF

The Company

CS Investment Funds 5 Investment Company with Variable Capital 5, rue Jean Monnet, L-2180 Luxembourg R.C.S. Luxembourg B 81.507

Board of Directors of the Company

Josef H.M. Hehenkamp Director, Credit Suisse AG, Zurich

Dominique Délèze Director, Credit Suisse AG, Zurich

Rudolf Kömen

Director, Credit Suisse Fund Management S.A., Luxembourg

Guy Reiter

Director, Credit Suisse Fund Management S.A., Luxembourg

Fernand Schaus

Director, Credit Suisse Fund Management S.A., Luxembourg

Auditor of the Company

PricewaterhouseCoopers, Société coopérative 2, rue Gerhard Mercator, L-2182 Luxembourg

Management Company

Credit Suisse Fund Management S.A. 5, rue Jean Monnet, L-2180 Luxembourg R.C.S. Luxembourg B 72.925

Board of Directors of the Management Company

Luca Diener, Member of the Board Managing Director, Credit Suisse AG, Zurich

Thomas Nummer, Member of the Board (since 01.12.2015) Independent Director, Luxembourg

Rudolf Kömen, Member of the Board Director, Credit Suisse Fund Management S.A., Luxembourg

Guy Reiter, Member of the Board Director, Credit Suisse Fund Management S.A., Luxembourg

Daniel Siepmann, Member of the Board (since 01.12.2015) Director, Credit Suisse Fund Services (Luxembourg) S.A., Luxembourg

Auditor of the Management Company

KPMG Luxembourg, Société coopérative 39, Avenue John F. Kennedy, L-1855 Luxembourg

Custodian Bank

Credit Suisse (Luxembourg) S.A. 5, rue Jean Monnet, L-2180 Luxembourg

Representative in Switzerland

Credit Suisse Funds AG Uetlibergstrasse 231, Postfach, CH-8070 Zurich

Paying Agent in Switzerland

Credit Suisse AG Paradeplatz, 8, CH-8001 Zurich

Information Agent in Germany

Credit Suisse (Deutschland) AG Junghofstrasse 16, D-60311 Frankfurt/Main

Paying Agent and Representative in Liechtenstein

LGT Bank in Liechtenstein AG Herrengasse 12, FL-9490 Vaduz

Paying Agent in Austria

UniCredit Bank Austria AG Schottengasse 6-8, A-1010 Vienna

Centralizing Agent in France

BNP PARIBAS Securities Services 3, rue d'Antin, F-75002 Paris Cedex 08

Distribution Agents

Credit Suisse AG Paradeplatz 8, CH-8001 Zurich

Credit Suisse Fund Services (Luxembourg) S.A., Luxembourg 5, rue Jean Monnet, L-2180 Luxembourg

Investment Managers

Credit Suisse AG Paradeplatz 8, CH-8001 Zurich

- Credit Suisse (Lux) Global Biotech Innovators Equity Fund
- Credit Suisse (Lux) Global Energy Winners Equity Fund
- Credit Suisse (Lux) Europe ILC Equity Fund
- Credit Suisse (Lux) Infrastructure Equity Fund
- Credit Suisse (Lux) Russian Equity Fund

Credit Suisse Asset Management LLC One Madison Avenue, New York, NY 10010 USA

 Credit Suisse (Lux) Global Small and Mid Cap Emerging Markets ILC Equity Fund

Credit Suisse Asset Management LLC
One Madison Avenue, New York, NY 10010 USA and
Credit Suisse (Singapore) Limited, 1 Raffles Link, #03-01, Singapore 039393 as
Co-Portfolio Managers of:

- Credit Suisse (Lux) Asia Pacific ILC Equity Fund

Credit Suisse (Singapore) Limited 1 Raffles Link, #03-01, Singapore 039393

- Credit Suisse (Lux) Asian Equity Dividend Plus Fund
- Credit Suisse (Lux) Asia Consumer Equity Fund

Central Administration

Credit Suisse Fund Services (Luxembourg) S.A., Luxembourg 5, rue Jean Monnet, L-2180 Luxembourg

No subscription may be accepted on the basis of the financial reports. Subscriptions are accepted only on the basis of the current sales prospectus accompanied by the key investor information documents, the latest annual report and the latest semi-annual report, if more recent.

The issue and redemption prices are published in Luxembourg at the registered office of the Management Company. The net asset value is also published daily on the Internet www.credit-suisse.com and in different newspapers.

Shareholders may obtain the sales prospectus, the key investor information documents, the latest annual and semi-annual reports, the changes in the composition of the securities portfolio during the reporting period and copies of the Articles of Association free of charge from the registered office of the Management Company or the local representatives in the countries where the Fund is registered or the Information Agent in Germany.

Consolidated Report Page 5

Statement of Net Assets in USD

	31.03.2016
Assets	
Investments in securities at market value	550,705,525.94
Cash at banks and at brokers	8,356,050.12
Subscriptions receivable	1,538,108.54
Income receivable	870,451.92
Net unrealised gain on forward foreign exchange contracts	1,145,698.08
	562,615,834.60
Liabilities Due to banks and to brokers	1,274,730.49
Redemptions payable	1,621,913.54
Provisions for accrued expenses	1,027,444.00
Net unrealised loss on forward foreign exchange contracts	59.09
Other liabilities	5,804.11
	3,929,951.23
Net assets	558,685,883.37

Consolidated Report Page 6

Statement of Operations / Changes in Net Assets in USD

For the period from 01.10.2015 to 31.03.2016

Net assets at the beginning of the period	632,201,399.43
Income	
Dividends (net)	4,145,299.66
Bank interest	1,408.86
Securities lending income	79,642.15
	4,226,350.67
Expenses	
Management fee	4,868,298.63
Custodian and safe custody fees	137,511.76
Administration expenses	297,713.62
Printing and publication expenses	96,742.02
Interest and bank charges	28,946.86
Audit, control, legal, representative bank and other expenses	515,808.43
"Taxe d'abonnement"	125,051.00
	6,070,072.32
Net income (loss)	-1,843,721.65
Realised gain (loss)	
Net realised gain (loss) on sales of investments	-27,323,339.48
Net realised gain (loss) on forward foreign exchange contracts	-2,556,214.51
Net realised gain (loss) on foreign exchange	100,465.90 -29,779,088.09
	., .,
Net realised gain (loss)	-31,622,809.74
Change in net unrealised appreciation (depreciation)	
Change in net unrealised appreciation (depreciation) Change in net unrealised appreciation (depreciation) on investments	8,545,644.56
Change in net unrealised appreciation (depreciation) on forward foreign exchange contracts	1,977,235.28
Grange in the difficulties appropriation (depreciation) on formal follogic overlaings contacts	10,522,879.84
Net increase (decrease) in net assets as a result of operations	-21,099,929.90
Tet mercuse (decrease) in net assets as a result of operations	21,000,020.00
Subscriptions / Redemptions	
Subscriptions	82,687,024.00
Redemptions	-135,674,373.33
	-52,987,349.33
Currency translation adjustment	571,763.17
Net assets at the end of the period	558,685,883.37

Notes Page 7

General

CS Investment Funds 5 (the "Company") is an undertaking for collective investment in transferable securities in the legal form of an investment company with variable capital (société d'investissement à capital variable, SICAV) subject to Part I of the amended Law of 17.12.2010. The Company was established on 18.04.2001.

The Company has an umbrella structure and therefore consists of at least one subfund.

As of 31.03.2016 the Company had 9 subfunds.

Changes

As at 16.12.2015 Credit Suisse (Lux) Biotechnology Equity Fund has been renamed in Credit Suisse (Lux) Global Biotech Innovators Equity Fund. As at 16.12.2015 Credit Suisse (Lux) Energy Equity Fund has been renamed in Credit Suisse (Lux) Global Energy Winners Equity Fund.

Summary of significant accounting policies

a) Presentation of financial statements

The financial statements are presented in accordance with the requirements of the Luxembourg supervisory authorities.

b) Computation of the net asset value of each subfund

The Net Asset Value of the Shares of each subfund shall be calculated in the Reference Currency of the respective subfund and shall be determined under the responsibility of the Company's Board of Directors in Luxembourg on each Banking Day on which banks are normally open all day for business in Luxembourg (each such day being referred to as a "Valuation Day").

The financial statements are presented on the basis of the latest NAV calculated during the financial period (i.e. 31.03.2016).

The investment manager needs to undertake transactions in order to maintain the desired asset allocation as a result of subscriptions or redemptions, which may generate additional costs for the fund and its shareholders. As a consequence, in order to protect the existing investors' interest, from these capital movements, when net capital movements exceed a threshold pre-defined by the Board of Directors, an adjustment of the NAV per share used is applied. This adjustment reflects the estimated tax and dealing costs that may be incurred by the fund as a result of these transactions, and the estimated bud-off spread of the assets in which the fund invests. A periodical review is undertaken in order to verify the appropriateness of the swing factor being applied.

The NAV per share as disclosed in the statistical information is the published NAV per share whereas the total net assets disclosed in the statement of net assets is the total net asset value excluding year end swing adjustment.

c) Valuation of investment securities of each subfund

Securities which are listed or regularly traded on a stock exchange shall be valued at the last available traded price. If such a price is not available for a particular trading day, the closing mid-price (the mean of the closing bid and ask prices) or alternatively the closing bid price may be taken as a basis for the valuation.

If a security is traded on several stock exchanges, the valuation shall be made by reference to the exchange which is the main market for this security.

If a security is traded on a secondary market with regulated trading among securities dealers (with the effect that the price reflects market conditions), the valuation may be based on this secondary market.

Securities traded on a regulated market shall be valued in the same way as those listed on a stock exchange.

Securities that are not listed on a stock exchange and are not traded on a regulated market shall be valued at their last available market price. If no such price is available, the Company shall value these securities in accordance with other criteria to be established by the Board of Directors and on the basis of the probable sales price, the value of which shall be estimated with due care and in good faith.

Derivatives shall be treated in accordance with the above. OTC swap transactions will be valued on a consistent basis based on bid, offer or mid prices as determined in good faith pursuant to procedures established by the Board of Directors. When deciding whether to use the bid, offer or mid-prices, the Board of Directors will take into consideration the anticipated subscription or redemption flows, among other parameters. If, in the opinion of the Board of Directors, such values do not reflect the fair market value of the relevant OTC swap transactions, the value of such OTC swap transactions will be determined in good faith by the Board of Directors or by such other method as it deems in its discretion

appropriate

The valuation price of a money market instrument which has a maturity or remaining term to maturity of less than 12 months and does not have any specific sensitivity to market parameters, including credit risk, shall, based on the net acquisition price or on the price at the time when the investment's remaining term to maturity falls below 12 months, be progressively adjusted to the repayment price while keeping the resulting investment return constant. In the event of a significant change in market conditions, the basis for the valuation of different investments shall be brought into line with the new market yields.

If a valuation in accordance with the above rules is rendered impossible or incorrect due to particular or changed circumstances, the Company's Board of Directors shall be entitled to use other generally recognized and auditable valuation principles in order to reach a proper valuation of the subfund's assets. Investments which are difficult to value (in particular those which are not listed on a secondary market with a regulated price-setting mechanism) are valued on a regular basis using comprehensible, transparent criteria. For the valuation of private equity investments, the Company may use the services of third parties which have appropriate experience and systems in this area. The Company's Board of Directors and the Auditor shall monitor the comprehensibility and transparency of the valuation methods and their application.

In exceptional circumstances, further valuations may be carried out on the same day; such valuations will be valid for any applications for subscription and/or redemption subsequently received.

d) Cash at banks and at brokers

Cash at banks and at brokers includes cash in hand, margin calls and deposits held at call with banks and other short-term investments in an active market with original maturities of three months or less and bank overdrafts.

e) Net realised gain/loss on sales of investments of each subfund

The realised gains or losses on the sales of securities are calculated on the basis of the average acquisition cost.

f) Foreign exchange conversion

The financial statements are kept in the reference currency of each subfund and the consolidated financial statements are kept in USD.

Cash at banks, other net assets and the value of portfolio securities in currencies other than the reference currency of each subfund are converted into the reference currency at the foreign exchange rate prevailing on the date of valuation.

Income and expenses in currencies other than the reference currency of each subfund are converted into the reference currency at the foreign exchange rate applicable at the date they accrue to the subfund.

Realised gains or losses on foreign currencies are accounted for in the statement of operations.

The acquisition cost of securities in currencies other than the reference currency of each subfund is converted into the reference currency at the foreign exchange rate valid at the date of acquisition.

- g) Transactions on investments in securities of each subfund The transactions on investments in securities are booked on a trade date basis.
- h) Valuation of forward foreign exchange contracts of each subfund Unmatured forward foreign exchange contracts are valued at valuation date at forward exchange rates prevailing at this date and resulting unrealised gains or losses are posted to the statement of operations and are shown under unrealised gain/loss on forward foreign exchange contracts in the statement of net assets.

i) Allocation of accrued expenses

Accrued expenses which can be allocated directly to a subfund are charged to this subfund. Accrued expenses which cannot be allocated directly are divided among the subfunds in proportion to the net assets of each subfund.

j) Securities Lending

The Company can practise lending of securities included in its portfolios of its subfunds. The Company may only lend securities within a standardized system of securities lending organised by a recognised institution of securities compensation or by first class financial institutions specialised in this type of operations. Notes Page 8

k) Income recognition

Dividends are recorded on ex-dividend date, net of withholding tax. Interests are accrued on a daily basis.

I) Other income

The trailer commissions received during the period/year are accounted under "Other income".

Management fee

(see detail at subfund level)

As remuneration for its services and reimbursement of its expenses, the Management Company is entitled to a monthly management fee, payable at the end of each month and calculated on the basis of the average of the daily net asset value of the relevant share class during that month. The rates shown in technical data are those as at 31.03.2016.

"Taxe d'abonnement"

Under the prevailing laws and regulations, the Company is subject in Luxembourg, on the basis of its investments, to a "taxe d'abonnement" at the annual rate of 0.05%, payable quarterly and calculated on the basis of the net assets of each subfund at the end of each quarter. In the case of Share Classes that may only be acquired by institutional investors, this annual tax rate is 0.01%.

The portion of net assets, which is invested in other undertakings for collective investment in securities under Luxembourg law, is exempt from this tax.

Total Expense Ratio (TER)

(see detail at subfund level)

The TER expresses the sum of all costs and commissions charged on an ongoing basis to the fund's assets, taken retrospectively as a percentage of these assets. The TER is calculated following the SFAMA guideline.

No TER is disclosed for share classes launched less than 6 months before closing.

Changes in the composition of the securities portfolio

Changes in the composition of the securities portfolio during the reporting period are available to Shareholders free of charge at the registered office of the Company or the local representatives in the countries where the Company is registered.

Exchange Rates

The consolidated financial statements are kept in USD. For this purpose, the financial statements of the subfunds are converted into USD at the foreign exchange rates as of 31.03.2016:

- 1 EUR = 1.139550 USD

Fund performance

(see detail at subfund level)

The performance is based on the net asset values as calculated on the last business day of the year. Those net asset values reflect the market prices of the investments as of the last business day of the year.

The YTD (Year-To-Date) Performance includes the period from 01.01.2016 until 31.03.2016.

Historical performance is no indicator of current or future performance.

The performance data given does not take into account commissions and costs incurred in the purchase or redemption of fund shares.

For shares launched more than 3 years ago no performance since inception is disclosed

Performance of distributing shares includes reinvestments of dividends.

Risk management

The global exposure of the subfunds will be calculated on the basis of the commitment approach.

Securities lending

As per 31.03.2016 the subfunds participated in the "securities lending" system with Credit Suisse AG as follows:

Subfund	Ссу	Stock lending market value	Collateral market Value
Credit Suisse (Lux) Asia Consumer Equity Fund	USD	631,635	670,176
Credit Suisse (Lux) Asian Equity Dividend Plus Fund	USD	0	0
Credit Suisse (Lux) Asia Pacific ILC Equity Fund	USD	0	0
Credit Suisse (Lux) Global Biotech Innovators Equity Fund	USD	7,413,607	7,865,966
Credit Suisse (Lux) Global Energy Winners Equity Fund	USD	5,626,098	5,969,388
Credit Suisse (Lux) Europe ILC Equity Fund	EUR	0	0
Credit Suisse (Lux) Global Small & Mid Cap	USD	0	0
Emerging Markets ILC Equity Fund Credit Suisse (Lux) Infrastructure Equity Fund	USD	618,065	655,778
Credit Suisse (Lux) Russian Equity Fund	EUR	3,648,306	3,870,916

The collateral delivered by the securities lending counterparty to the Company is composed of a well diversified portfolio of securities consisting of

- highly rated bonds issued or guaranteed by governments, government agencies, bodies regulated by public law or corporations (excluding Credit Suisse affiliates) from selected OECD countries.
- highly rated bonds from supranational organisations
- equities listed on selected stock exchanges within the OECD on the condition that the shares are included in a main and liquid index.

The determination of the market value of the collateral is subject to the application of appropriate haircuts adapted to the volatility of the collateral type.

The revenues mentioned in the Statement of Operations / Changes in Net Assets under "Security Lending Income" are the net amounts received from the lending principal. Any direct and indirect operational costs and fees are borne by the principal out of its fee and include the liability risk assumed by the principal.

For the period ended on 31.03.2016, the fee paid to the principal amounted to as follows:

Subfund	Ссу	Gross amount securities lending Income	Expenses and commissions from the securities lending counterparty	amount
Credit Suisse (Lux) Asia Consumer Equity Fund	USD	3,387.40	1,354.96	2,032.44
Credit Suisse (Lux) Asian Equity Dividend Plus Fund	USD	1,973.48	789.39	1,184.09
Credit Suisse (Lux) Asia Pacific ILC Equity Fund Credit Suisse (Lux) Global Biotech	USD	-	-	-
Innovators Equity Fund Credit Suisse (Lux) Global Energy	USD	35,551.47	14,220.59	21,330.88
Winners Equity Fund Credit Suisse (Lux) Europe ILC Equity	USD	24,109.80	9,643.92	14,465.88
Fund Credit Suisse (Lux) Global Small & Mid Cap	EUR	141.38	56.55	84.83
Emerging Markets ILC Equity Fund	USD	1,784.67	713.87	1,070.80
Credit Suisse (Lux) Infrastructure Equity Fund	USD	16,857.90	6,743.16	10,114.74
Credit Suisse (Lux) Russian Equity Fund	USD	50,695.75	20,278.30	30,417.45

Notes Page 9

Transaction costs

Transactions costs include brokerage fees, stamp duty, local taxes and other foreign charges if incurred during the period. Transaction costs are included in the cost of securities purchased and sold.

For the period ended on 31.03.2016, the Company incurred transaction costs relating to purchase or sale of investments in securities and similar transactions, (including derivatives instruments or other eligible assets) as follows:

Subfund	CCY	Amount
Credit Suisse (Lux) Asia Consumer Equity Fund	USD	62,476.33
Credit Suisse (Lux) Asian Equity Dividend Plus Fund	USD	46,652.47
Credit Suisse (Lux) Biotech Innovators Equity Fund	USD	17,698.82
Credit Suisse (Lux) Global Energy Winners		
Equity Fund	USD	49,171.63
Credit Suisse (Lux) Global Small and Mid Cap		
Emerging Markets ILC Equity Fund	USD	372,618.78
Credit Suisse (Lux) Infrastructure Equity Fund	USD	193,903.70
Credit Suisse (Lux) Russian Equity Fund	USD	62,238.95

Not all transaction costs are separately identifiable. For fixed income investments, forward foreign exchange contracts and for some other derivative contracts, transaction costs will be included in the purchase and sales price of the investment. Whilst not separately identifiable these transaction costs will be captured within the performance of each subfund.

Financial Derivative Instruments

The subfunds may engage in derivative transactions for the purpose of efficient portfolio management. Details of the derivatives are displayed in the Notes pages.

Depending on the type of derivatives held, collateral might be received from the different counterparts to reduce the counterparty exposure. For other type of derivatives, margin accounts might be used.

No collateral was received by the Company to reduce the counterparty risk as of 31.03.2016.

Subsequent event

There is no event subsequent.

Technical Data

		Valoren	ISIN	Management Fee	Total Expense Ratio
B -Capitalisation	USD	4491453	LU0383587234	1.92%	2.41%
UB -Capitalisation	USD	26377248	LU1144413504	1.15%	1.66%
BH -Capitalisation	CHF	4491484	LU0383588042	1.92%	2.42%
UBH -Capitalisation	CHF	26377250	LU1144413686	1.15%	1.64%
BH -Capitalisation	EUR	4491436	LU0383586699	1.92%	2.42%
UBH -Capitalisation	EUR	26377252	LU1144413769	1.15%	1.66%

Fund Performance

		YTD	Since Inception	2015	2014	2013
B -Capitalisation	USD	-5.19%	/	-10.37%	-4.29%	9.02%
UB -Capitalisation	USD	-5.01%	-16.06%	/	/	/
BH -Capitalisation	CHF	-5.60%	/	-11.44%	-4.73%	8.41%
UBH -Capitalisation	CHF	-5.41%	-17.38%	/	/	/
BH -Capitalisation	EUR	-5.44%	/	-10.36%	-4.54%	8.47%
UBH -Capitalisation	EUR	-5.26%	-16.45%	/	/	/

Notes

Forward foreign exchange contracts

Purchases		Sales		Maturity	Valuation
Counterparty					(in USD)
CHF	2,169,139.30	USD	-2,210,096.81	15.06.2016	62,920.41
Credit Suisse Zürich					
EUR	4,415,954.77	USD	-4,923,771.91	15.06.2016	120,559.98
Credit Suisse Zürich					
CHF	30,454.15	USD	-31,589.67	15.06.2016	322.90
Credit Suisse Zürich					
CHF	12,047.90	USD	-12,476.33	15.06.2016	148.53
Credit Suisse Zürich					
EUR	134,243.92	USD	-151,411.16	15.06.2016	1,935.27
Credit Suisse Zürich					
CHF	78,038.60	USD	-80,786.93	15.06.2016	988.86
Credit Suisse Zürich					
Net unrealised gain	on forward foreign e	xchange contracts			186,875.95

Statement of Net Assets in USD and Fund Evolution

	31.03.2016
Assets	
Investments in securities at market value	15,841,592.54
Cash at banks and at brokers	522,378.82
Subscriptions receivable	932.74
Income receivable	28,852.15
Net unrealised gain on forward foreign exchange contracts	186,875.95
	16,580,632.20
Liabilities	
Due to banks and to brokers	184,015.21
Provisions for accrued expenses	32,785.10
Other liabilities	1.74
	216,802.05
Net assets	16,363,830.15

Fund Evolution		31.03.2016	30.09.2015	30.09.2014
Total net assets	USD	16,363,830.15	18,821,140.04	40,371,678.87
Net asset value per share				
B -Capitalisation	USD	154.96	157.19	181.45
UB -Capitalisation	USD	83.94	84.82	/
BH -Capitalisation	CHF	139.15	142.34	165.71
UBH -Capitalisation	CHF	82.62	84.17	/
BH -Capitalisation	EUR	147.10	150.03	172.75
UBH -Capitalisation	EUR	83.55	84.84	/

Number of shares outstanding		at the end of the period	at the beginning of the period	Number of shares issued	Number of shares redeemed
B -Capitalisation	USD	52,850.144	64,235.105	6,233.539	17,618.500
UB -Capitalisation	USD	6,670.135	6,027.695	3,800.135	3,157.695
BH -Capitalisation	CHF	15,455.272	14,885.400	1,761.872	1,192.000
UBH -Capitalisation	CHF	1,464.851	383.851	1,081.000	0.000
BH -Capitalisation	EUR	30,572.068	35,759.135	150.000	5,337.067
UBH -Capitalisation	EUR	439.700	239.902	199.798	0.000

Statement of Operations / Changes in Net Assets in USD

For the period from 01.10.2015 to 31.03.2016

Net assets at the beginning of the period	18,821,140.04
Income	
Dividends (net)	66,710.26
Securities lending income	2,032.44
	68,742.70
Expenses	
Management fee	165,971.05
Custodian and safe custody fees	3,953.01
Administration expenses	8,778.86
Printing and publication expenses	5,671.01
Interest and bank charges	2,691.58
Audit, control, legal, representative bank and other expenses	21,310.05
"Taxe d'abonnement"	4,475.36
	212,850.92
Net income (loss)	-144,108.22
Realised gain (loss)	
Net realised gain (loss) on sales of investments	-1,085,773.83
Net realised gain (loss) on forward foreign exchange contracts	-285,930.82
Net realised gain (loss) on foreign exchange	36,666.58
	-1,335,038.07
Net realised gain (loss)	-1,479,146.29
Change in net unrealised appreciation (depreciation)	
Change in net unrealised appreciation (depreciation) on investments	1,150,889.72
Change in net unrealised appreciation (depreciation) on forward foreign exchange contracts	286,123.49
	1,437,013.21
Net increase (decrease) in net assets as a result of operations	-42,133.08
Subscriptions / Redemptions	
Subscriptions Subscriptions	1,616,996.79
Redemptions	-4,032,173.60
redelliptions	-4,032,173.80 -2,415,176.81
Not assets with a seed of the seeded	40.000.000.00
Net assets at the end of the period	16,363,830.15

Breakdown by Country and Economic Sector of the Investments in Securities Statement of Investments in Securities and Other Net Assets

Breakdown by Country

Cayman Islands	29.81
South Korea	14.95
Hong Kong	13.10
Taiwan	9.34
People's Republic of China	7.19
Philippines	6.48
Indonesia	6.04
Japan	4.54
United Kingdom	1.57
Bermuda	1.31
India	1.28
Thailand	1.20
Total	96.81

Breakdown by Economic Sector

Pharmaceuticals, cosmetics and medical products	13.93
Internet, software and IT services	13.19
Real estate	10.32
Electrical appliances and components	6.64
Insurance companies	6.22
Banks and other credit institutions	6.10
Textiles, garments and leather goods	5.71
Lodging and catering industry, leisure facilities	5.59
Electronics and semiconductors	5.31
Building materials and building industry	5.10
Telecommunication	4.19
Miscellaneous services	4.05
Biotechnology	3.55
Forestry, paper and forest products	2.70
Retailing, department stores	1.97
Photographic and optics	1.28
Food and soft drinks	0.89
Tobacco and alcoholic beverages	0.07
Total	96.81

Statement of Investments in Securities and Other Net Assets

	Description	Quantity / Nominal	Valuation (in USD)	% of net assets
Secu	ities listed on a stock exchange or other organise	ed markets: Share	s (and equity-type	securities)
Share	es (and equity-type securities)			
HKD	AIA GROUP	117,500.00	665,778.02	4.07
USD	ALIBABA ADR	6,800.00	537,404.00	3.28
KRW	AMOREPACIFIC (new)	2,470.00	834,780.47	5.10
HKD	ANTA SPORTS PRODUCTS	127,000.00	279,656.10	1.71
PHP	AYALA LAND	380,000.00	290,910.95	1.78
USD	BAIDU.COM ADR	1,850.00	353,128.00	2.16
HKD	BEST PACIFIC INTERNATIONAL HOLDINGS	526,000.00	290,243.31	1.77
HKD	BLOOMAGE BIOTECHNOLOGY	265,000.00	580,117.90	3.55
TWD	CATCHER TECHNOLOGY	44,000.00	360,924.95	2.21
HKD	CHINA MOBILE	61,500.00	685,445.33	4.19
HKD	CHINA WOBILE CHINA VANKE -H-	176,000.00	431,574.61	2.64
TWD	ECLAT TEXTILE	23,000.00	302,650.61	1.85
HKD	GALAXY ENTERTAINMENT GROUP		450,201.51	2.75
KRW		120,000.00		
HKD	HOTEL SHILLA INDUSTRIAL AND COMMERCIAL BANK OF	6,794.00 680,000.00	395,069.06 380,479.58	2.41 2.33
	CHINA -H-			
USD	INFOSYS ADR	11,000.00	209,220.00	1.28
USD	JD.COM ADR	21,000.00	556,500.00	3.40
GBP	JIMMY CHOO	139,594.00	257,014.82	1.57
THB	KASIKORNBANK units (nvdr)	40,000.00	196,702.77	1.20
JPY	KOSE	3,500.00	340,984.85	2.08
CNH	KWEICHOW MOUTAI -A-	300.00	11,504.05	0.07
HKD	KWG PROPERTY HOLDING	520,000.00	341,905.61	2.09
TWD	LARGAN PRECISION	2,700.00	209,312.24	1.28
KRW	LG HOUSEHOLD & HEALTHCARE	850.00	702,387.16	4.29
PHP	MEGAWORLD CORPORATION	4,790,000.00	431,718.80	2.64
IDR	MITRA ADIPERKASA	349,200.00	126,407.23	0.77
HKD	PAX GLOBAL TECHNOLOGY	214,000.00	214,095.83	1.31
HKD	PING AN INSURANCE COMPANY OF CHINA -H-	73,600.00	352,033.86	2.15
IDR	PT BANK MANDIRI (PERSERO)	541,400.00	420,544.47	2.57
IDR	PT SUMMARECON AGUNG TBK	3,700,000.00	442,269.96	2.70
TWD	RADIANT OPTO-ELECTRONICS	102,000.00	197,763.01	1.21
KRW	SAMSUNG ELECTRONICS	450.00	516,264.40	3.15
HKD	SANDS CHINA	127,600.00	519,840.92	3.18
HKD	SHIMAO PROPERTY HOLDINGS	260,000.00	384,811.41	2.35
JPY	SHISEIDO	18,000.00	402,295.39	2.46
HKD	SITOY GROUP HOLDINGS	303,000.00	95,315.86	0.58
PHP	SM PRIME HOLDINGS	400,000.00	190,682.95	1.17
USD	TAIWAN SEMICONDUCTOR MANUFACTURING	17,400.00	455,880.00	2.79
030	ADR	17,400.00	400,000.00	2.18
HKD	TENCENT HOLDINGS	47,000.00	959,811.05	5.86
PHP	UNIVERSAL ROBINA	31,000.00	145,961.50	0.89
USD	VIPSHOP HOLDINGS ADR	25,000.00	322,000.00	1.97
Share	es (and equity-type securities)		15,841,592.54	96.81
Secu	rities listed on a stock exchange or other organise	ed markets:		
	es (and equity-type securities)		15,841,592.54	96.81
	of Portfolio		15,841,592.54	96.81
Cash a	at banks and at brokers		522,378.82	3.19
Due to	b banks and to brokers		-184,015.21	-1.12
Other	net assets		183,874.00	1.12
Total	net assets		16,363,830.15	100.00

Technical Data

		Valoren	ISIN	Management Fee	Total Expense Ratio
B -Capitalisation	USD	25288602	LU1103911886	1.60%	1.97%
EB -Capitalisation	USD	25290393	LU1103912009	0.50%	0.83%
IB -Capitalisation	USD	25290409	LU1103912181	0.70%	1.07%
UB -Capitalisation	USD	27509868	LU1205642777	0.95%	1.37%

Fund Performance

		YTD	Since Inception
		110	Since inception
B -Capitalisation	USD	-2.28%	-22.80%
EB -Capitalisation	USD	-1.90%	-21.92%
IB -Capitalisation	USD	-1.96%	-22.10%
UB -Capitalisation	USD	-1.98%	-15.70%

Statement of Net Assets in USD and Fund Evolution

	31.03.2016
Assets	
Investments in securities at market value	15,331,194.37
Cash at banks and at brokers	233,988.47
Income receivable	65,972.05
	15,631,154.89
Liabilities	
Due to banks and to brokers	211.80
Provisions for accrued expenses	12,384.74
	12,596.54
Net assets	15,618,558.35

Fund Evolution		31.03.2016	30.09.2015
Total net assets	USD	15,618,558.35	15,855,818.70
Net asset value per share			
B -Capitalisation	USD	7.72	7.88
EB -Capitalisation	USD	780.81	792.51
IB -Capitalisation	USD	779.01	791.63
UB -Capitalisation	USD	8.43	8.58

Number of shares outstanding		at the end of the period	at the beginning of the period	Number of shares issued	Number of shares redeemed
B -Capitalisation	USD	50,000.000	50,000.000	0.000	0.000
EB -Capitalisation	USD	18,500.000	18,500.000	0.000	0.000
IB -Capitalisation	USD	1,000.000	1,000.000	0.000	0.000
UB -Capitalisation	USD	1,000.000	1,000.000	0.000	0.000

Page 16

Statement of Operations / Changes in Net Assets in USD

For the period from 01.10.2015 to 31.03.2016

Net assets at the beginning of the period	15,855,818.70
Income	
Dividends (net)	151,258.17
Bank interest	338.06
	151,596.23
Expenses	
Management fee	41,719.50
Custodian and safe custody fees	3,317.69
Administration expenses	7,728.09
Printing and publication expenses	3,604.13
Audit, control, legal, representative bank and other expenses	14,958.25
"Taxe d'abonnement"	1,025.18
	72,352.84
Net income (loss)	79,243.39
Realised gain (loss)	
Net realised gain (loss) on sales of investments	-1,207,393.19
Net realised gain (loss) on forward foreign exchange contracts	91.18
Net realised gain (loss) on foreign exchange	-9,055.20
	-1,216,357.21
Net realised gain (loss)	-1,137,113.82
Change in net unrealised appreciation (depreciation)	
Change in net unrealised appreciation (depreciation) on investments	899,853.47
	899,853.47
Net increase (decrease) in net assets as a result of operations	-237,260.35
Subscriptions / Redemptions	
Subscriptions	0.00
Redemptions	0.00
	0.00
Net assets at the end of the period	15,618,558.35

Breakdown by Country and Economic Sector of the Investments in Securities Statement of Investments in Securities and Other Net Assets

Breakdown by Country	
Australia	19.36
South Korea	16.74
Taiwan	13.94
People's Republic of China	10.19
Cayman Islands	9.73
Thailand	5.71
Hong Kong	4.87
Bermuda	3.89
Singapore	3.49
France	2.08
Luxembourg	2.07
New Zealand	1.66
India	1.55
Malaysia	1.18
USA	1.10
Indonesia	0.50
United Kingdom	0.10
Total	98.16

Breakdown by Economic Sector	10.40
Banks and other credit institutions	19.40
Electronics and semiconductors	10.44
Telecommunication	8.95
Financial, investment and other div. companies	8.35
Electrical appliances and components	7.04
Investment trusts/funds	6.64
Petroleum	6.05
Internet, software and IT services	4.36
Insurance companies	2.94
Real estate	2.91
Pharmaceuticals, cosmetics and medical products	2.72
Textiles, garments and leather goods	2.35
Tobacco and alcoholic beverages	1.91
Traffic and transportation	1.66
Healthcare and social services	1.53
Miscellaneous consumer goods	1.44
Energy and water supply	1.24
Vehicles	1.24
Building materials and building industry	1.07
Miscellaneous services	1.05
Mining, coal and steel industry	0.92
Mortgage and funding institutions (MBA, ABS)	0.88
Mechanical engineering and industrial equipment	0.84
Computer hardware and networking	0.73
Retailing, department stores	0.55
Graphics publishing and printing media	0.50
Food and soft drinks	0.45
Total	98.16

	Description	Quantity / Nominal	(in USD)	% of ne asset
Secu	rities listed on a stock exchange or other organise	d markets: Share	es (and equity-type	securities
Share	es (and equity-type securities)			
HKD	AGRICULTURAL BANK OF CHINA -H-	723,000.00	260,060.99	1.6
NZD KRW	AIR NEW ZEALAND AMOREPACIFIC (new)	130,800.00 300.00	259,728.25 101,390.34	1.6 0.6
HKD	ANTA SPORTS PRODUCTS	78,000.00	171,757.29	1.1
AUD	AUSTRALIA & NEW ZEALAND BANKING GROUP	23,000.00	415,065.74	2.6
THB	BANGCHAK PETROLEUM NVDR	415,400.00	345,379.64	2.2
IDR	BANK PEMBANGUNAN DAERAH JAWA BARAT & BANTEN	1,067,200.00	77,665.76	0.5
HKD	BELLE INTERNATIONAL HOLDINGS	175,000.00	101,301.79	0.6
AUD	BENDIGO AND ADELAIDE BANK	21,800.00	148,744.58	0.9
AUD	BHP BILLITON	11,100.00	143,959.92	0.9
TWD	CATCHER TECHNOLOGY	33,000.00	270,693.71	1.7
USD	CHINA BIOLOGIC PRODUCTS	1,500.00	171,720.00	1.1
HKD	CHINA CONSTRUCTION BANK -H-	666,000.00	425,022.71	2.7
HKD HKD	CHINA LESSO GROUP HOLDINGS CHINA MOBILE	245,000.00 34,000.00	131,399.02 378,945.39	0.8 2.4
HKD	CHINA POWER INTERNATIONAL	162,000.00	83,960.26	0.5
	DEVELOPMENT			
TWD	CHLITINA HOLDING	8,000.00	68,854.14	0.4
HKD	CHONGQING RURAL COMMERCIAL BANK -H-	458,000.00	242,092.89	1.5
KRW	CJ CGV	900.00	77,675.76	0.5
TWD AUD	CORETRONIC CYBG	145,000.00	148,000.67	0.9
SGD	DBS GROUP HOLDINGS	5,225.00 15,200.00	15,835.93 173,601.02	1.1
AUD	DEXUS PROPERTY GROUP (stapled security)	17,100.00	104,442.60	0.6
KRW	DGB FINANCIAL GROUP	18,200.00	141,640.43	0.9
JSD	DR REDDY'S LABORATORIES ADR	2,300,00	103,937.00	0.6
TWD	ECLAT TEXTILE	7,160.00	94,216.45	0.6
HKD	FAR EAST HORIZON	385,000.00	296,821.00	1.9
ΓWD	GIGA-BYTE TECHNOLOGY	104,000.00	114,715.47	0.7
HKD	HAIER ELECTRONICS GROUP	132,000.00	230,082.36	1.4
KRW	HANSSEM	800.00	156,348.37	1.0
TWD	HON HAI PRECISION INDUSTRY	140,800.00	370,987.10	2.3
HKD	HUANENG POWER INTERNATIONAL	216,000.00	193,261.76	1.2
JSD	INDIABULLS HOUSING (REGS-)	14,000.00	136,668.00	0.8
JSD	JARDINE STRATEGIC HOLDINGS	4,400.00	131,340.00	0.8
HKD KRW	KERRY PROPERTIES KIA MOTORS	58,500.00 4,600.00	160,645.36 194,281.21	1.0
THB	KRUNG THAI BANK (nvdr)	192,700.00	102,430.12	0.6
KRW	KT CORPORATION	6,500.00	169,377.40	1.0
KRW	KT& G CORP	3,100.00	298,181.17	1.9
KRW	LG HOUSEHOLD & HEALTHCARE	100.00	82,633.78	0.5
KRW	LG UPLUS	26,900.00	259,920.41	1.6
HKD	LUK FOOK HOLDINGS	38,000.00	86,224.16	0.5
AUD	MACQUARIE GROUP	6,400.00	325,369.45	2.0
KRW	MEDY-TOX	350.00	135,121.54	3.0
AUD	MIRVAC GROUP	127,400.00	189,631.92	1.2
MYR AUD	MY E.G.SERICES BERHAD NATIONAL AUSTRALIA BANK	334,700.00 14,900.00	183,585.47 300,753.81	1.1
HKD	NEW CHINA LIFE INSURANCE -H-	30,100.00	106,134.49	0.6
TWD	PEGATRON	95,000.00	221,678.64	1.4
TWD	PHISON ELECTRONICS	10,000.00	81,406.97	0.5
HKD	PING AN INSURANCE COMPANY OF CHINA -H-	57,000.00	272,634.92	1.5
THB	PTT GLOBAL CHEMICAL PUBLIC (nvdr)	151,500.00	260,538.78	1.6
THB	PTT PUBLIC COMPANY LIMITED (nvdr)	14,200.00	113,018.81	0.7
AUD	QBE INSURANCE GROUP	9,400.00	78,888.49	0.5
KRW	SAMSUNG ELECTRONICS	595.00	682,616.26	4.3
SGD	SEMBCORP INDUSTRIES	58,600.00	131,418.62	0.8
HKD	SHIMAO PROPERTY HOLDINGS	113,000.00	167,244.96	1.0
HKD	SINOPEC ENGINEERING (GROUP) -H- STOCKLAND TRUST	111,500.00	90,274.94	0.8
AUD		118,600.00	389,559.33	2.4
JSD	TAIWAN SEMICONDUCTOR MANUFACTURING TAL EDUCATION GROUP -A- ADR	145,000.00 4,800.00	729,866.31 238,464.00	4.6
AUD	TELSTRA	87,900.00	360,393.65	2.3
HKD	TENCENT HOLDINGS	24,300.00	496,242.73	3.
THB	THAI VEGETABLE OIL PUBLIC NON VOTING	105,600.00	70,239.94	0.4
	DEPOSITARY RECEIPT			
TWD	TUNG THIH ELECTRONIC	9,000.00	148,210.40	0.9
SGD	UNITED OVERSEAS BANK	17,200.00	241,019.78	1.5
AUD	WESFARMERS	13,500.00	430,446.67	2.'
AUD	WOODSIDE PETROLEUM	6,800.00	135,792.14	
(RW -IKD	WOORI BANK XINIY GLASS HOLDINGS	38,400.00 216.000.00	317,649.51 143,971.66	2.0
IND	AINIT GLASS HOLDINGS	210,000.00	145,971.00	0.3
Share	es (and equity-type securities)		14,683,184.14	94.0
	rities listed on a stock exchange or other organise es (and equity-type securities)	d markets:	14,683,184.14	94.0
	rities listed on a stock exchange or other organise	d markets: Invest		54.0
	units (Open-End)			
		0.700.00	202 054 60	
EUR EUR	DB X-TRACKERS S&P CNX NIFTY -1C- LYXOR INTERNATIONAL ASSET MANAGEMENT	2,700.00 21,900.00	323,954.69 324,055.54	2.0
_014	- LYXOR ETF MSCI INDIA -A-	21,500.00	024,000.04	۷.۱
und	units (Open-End)		648,010.23	4.
Secu	rities listed on a stock exchange or other organise	d markets:		
nves	tment funds		648,010.23	4.

Statement of Investments in Securities and Other Net Assets (Continued)

Description	Quantity / Nominal	Valuation (in USD)	% of net assets
Total of Portfolio		15,331,194.37	98.16
Cash at banks and at brokers		233,988.47	1.50
Due to banks and to brokers		-211.80	/
Other net assets		53,587.31	0.34
Total net assets		15 618 558 35	100.00

Technical Data

		Valoren	ISIN	Management Fee	Total Expense Ratio
B -Capitalisation	USD	10258773	LU0434327028	1.92%	2.40%
EB -Capitalisation	USD	19077250	LU0808572092	0.90%	/
IB -Capitalisation	USD	19077394	LU0808572415	0.90%	1.36%
UB -Capitalisation	USD	26374586	LU1144413413	1.15%	1.67%

 $\label{thm:condition} \textit{Credit Suisse (Lux) Asian Equity Dividend Plus Fund EB - USD- \ has been liquidated as at 23.04.2015.}$

Fund Performance

		YTD	Since Inception	2015	2014	2013
B -Capitalisation	USD	0.12%	/	-13.96%	-0.51%	-1.07%
EB -Capitalisation	USD	/	/	/	0.62%	0.96%
IB -Capitalisation	USD	0.37%	/	-13.08%	0.51%	-0.05%
UB -Capitalisation	USD	0.32%	-15.29%	/	/	/

Statement of Net Assets in USD and Fund Evolution

	31.03.2016
Assets	
Investments in securities at market value	15,649,921.83
Cash at banks and at brokers	461,642.49
Income receivable	66,421.40
	16,177,985.72
Liabilities	
Provisions for accrued expenses	34,039.67
	34,039.67
Net assets	16,143,946.05

Fund Evolution		31.03.2016	30.09.2015	30.09.2014	
Total net assets	USD	16,143,946.05	19,205,715.15	40,164,102.38	
Total lict dissets	000	10,140,340.00	13,200,110.10	40,104,102.00	
Net asset value per share					
B -Capitalisation	USD	121.73	119.04	139.49	
EB -Capitalisation	USD	/	855.81	992.20	
IB -Capitalisation	USD	819.36	797.15	924.54	
UB -Capitalisation	USD	84.71	82.51	/	

Number of shares outstanding		at the end of the period	at the beginning of the period	Number of shares issued	Number of shares redeemed
B -Capitalisation	USD	128,286.655	157,120.387	8,565.007	37,398.739
EB -Capitalisation	USD	0.000	9.836	0.000	9.836
IB -Capitalisation	USD	450.279	490.359	0.000	40.080
UB -Capitalisation	USD	1,869.685	1,248.798	620.887	0.000

Statement of Operations / Changes in Net Assets in USD

For the period from 01.10.2015 to 31.03.2016

Net assets at the beginning of the period	19,205,715.15
Income	
Dividends (net)	168,559.08
Securities lending income	1,184.09
	169,743.17
Expenses	
Management fee	163,130.64
Custodian and safe custody fees	3,880.12
Administration expenses	8,617.50
Printing and publication expenses	4,218.18
Interest and bank charges	2,621.39
Audit, control, legal, representative bank and other expenses	24,523.55
"Taxe d'abonnement"	4,170.89
	211,162.27
Net income (loss)	-41,419.10
Destination (see)	
Realised gain (loss) Net realised gain (loss) on sales of investments	-1,740,732.11
Net realised gain (loss) on forward foreign exchange contracts	-1,740,732.11
Net realised gain (loss) on foreign exchange	2,316.83
Tret realised gain (loss) on foreign exchange	-1,738,456.56
Net realised gain (loss)	-1,779,875.66
	, ,,,
Change in net unrealised appreciation (depreciation)	0 160 424 02
Change in net unrealised appreciation (depreciation) on investments	2,168,434.23 2,168,434.2 3
	_,,,
Net increase (decrease) in net assets as a result of operations	388,558.57
Subscriptions / Redemptions	
Subscriptions	1,034,641.07
Redemptions	-4,484,968.74
	-3,450,327.67

Breakdown by Country and Economic Sector of the Investments in Securities Statement of Investments in Securities and Other Net Assets

Breakdown	by Country
-----------	------------

Australia	21.04
Hong Kong	12.69
Cayman Islands	10.12
South Korea	9.34
People's Republic of China	9.28
Taiwan	8.73
Singapore	6.07
Indonesia	4.84
Thailand	4.55
Philippines	2.32
India	2.29
Luxembourg	1.86
USA	1.50
Malaysia	1.29
United Kingdom	1.02
Total	96.94

Breakdown by Economic Sector

Banks and other credit institutions	13.91
Telecommunication	12.69
Real estate	6.98
Financial, investment and other div. companies	6.93
Building materials and building industry	6.13
Insurance companies	5.28
Petroleum	5.01
Electrical appliances and components	4.74
Electronics and semiconductors	4.60
Traffic and transportation	3.51
Investment trusts/funds	3.36
Internet, software and IT services	3.21
Textiles, garments and leather goods	3.07
Mining, coal and steel industry	2.25
Agriculture and fishery	2.12
Packaging industries	2.05
Miscellaneous services	1.88
Pharmaceuticals, cosmetics and medical products	1.88
Mechanical engineering and industrial equipment	1.79
Lodging and catering industry, leisure facilities	1.26
Chemicals	1.24
Vehicles	1.02
Non-ferrous metals	1.02
Food and soft drinks	1.01
Total	96.94

Statement of Investments in Securities and Other Net Assets

	Description	Quantity / Nominal	Valuation (in USD)	% of net assets
Secu	rities listed on a stock exchange or other organise	ed markets: Share	es (and equity-type	securities)
Share	es (and equity-type securities)			
HKD	AIA GROUP	55,000.00	311,640.78	1.93
USD	ALIBABA ADR	2,000.00	158,060.00	0.98
AUD HKD	AMCOR ANTA SPORTS PRODUCTS	30,000.00	331,157.20	2.05
THB	ASIAN PROPERTY DEVELOPMENT PUBLIC	90,000.00 1,600,000.00	198,181.49 277,430.49	1.23 1.72
1110	(nvdr)	1,000,000.00	211,400.40	1.12
IDR	ASTRA AGRO LESTARI	120,000.00	164,705.87	1.02
PHP	AYALA LAND	250,000.00	191,388.78	1.19
USD	BAIDU.COM ADR BHP BILLITON	900.00	171,792.00	1.06
AUD		28,000.00	363,142.14 179,075.00	2.25
HKD TWD	BOC HONG KONG CATHAY FINANCIAL HOLDING	60,000.00 180,000.00	215,604.19	1.11
HKD	CHEUNG KONG INFRASTRUCTURE HOLDINGS	30,000.00	293,365.84	1.82
HKD	CHINA CONSTRUCTION BANK -H-	600,000.00	382,903.34	2.37
HKD	CHINA MERCHANT BANK -H-	70,000.00	147,101.92	0.91
HKD	CHINA MOBILE	50,000.00	557,272.63	3.45
HKD	CHINA VANKE -H-	100,000.00	245,212.85	1.52
HKD	CNOOC	170,000.00	200,759.96	1.24
SGD	DBS GROUP HOLDINGS	22,000.00	251,264.63	1.56
TWD	FAR EASTONE TELECOM	90,000.00	201,622.07	1.25
PHP	GLOBE TELECOM	3,800.00	183,212.00	1.13
HKD	HENGAN INTERNATIONAL GROUP	35,000.00	303,679.74	1.88
HKD	HKT (stapled security)	200,000.00	275,380.99	1.71
USD	ICICI BANK ADR	25,000.00	179,000.00	1.11
USD	INFOSYS ADR	10,000.00	190,200.00	1.18
AUD KRW	INSURANCE AUSTRALIA GROUP KEPCO PLANT SERVICES & ENGINEERING	75,000.00	321,926.34	1.99 0.90
SGD	KEPPEL DC REIT TRUST (regS-)	2,600.00 300,000.00	145,732.77 236,145.38	1.46
HKD	KWG PROPERTY HOLDING	350,000.00	230,128.78	1.43
KRW	LG CHEMICAL	700.00	200,463.44	1.24
AUD	MACQUARIE GROUP	9,300.00	472,802.48	2.93
KRW	MACQUARIE KOREA INFRASTRUCTURE FUND	43,000.00	314,716.67	1.95
MYR	MALAYAN BANKING	90,000.00	208,074.02	1.29
AUD	NATIONAL AUSTRALIA BANK	21,000.00	423,881.22	2.63
HKD	PING AN INSURANCE COMPANY OF CHINA -H-	46,000.00	220,021.16	1.36
IDR	PT ASTRA INTERNATIONAL	300,000.00	164,027.14	1.02
IDR	PT INDOFOOD SUKSES MAKMUR	300,000.00	163,461.53	1.01
IDR	PT TELEKOMUNIKASI INDONESIA -B-	1,150,000.00	288,367.26	1.79
THB	PTT PUBLIC COMPANY LIMITED (nvdr)	35,000.00	278,567.50	1.73
AUD	RIO TINTO	5,000.00	164,193.97	1.02
TWD		180,000.00	296,420.80	1.84
KRW	SAMSUNG ELECTRONICS	290.00	332,703.72	2.06
KRW	SAMSUNG ELECTRONICS (pref. shares)	250.00	241,998.94	1.50
HKD	SANDS CHINA SHIMAO PROPERTY HOLDINGS	50,000.00	203,699.42	1.26
SGD	SINGAPORE TELECOMMUNICATIONS	170,000.00 95,000.00	251,607.46 269,487.92	1.56 1.67
KRW	SK TELECOM	1,500.00	273,478.47	1.69
AUD	SYDNEY AIRPORT (stapled security)	110,000.00	566,082.65	3.51
TWD	TAIWAN CEMENT	170,000.00	166,387.15	1.03
TWD	TAIWAN SEMICONDUCTOR MANUFACTURING	105,000.00	528,523.88	3.27
HKD	TENCENT HOLDINGS	17,000.00	347,165.70	2.15
THB	THAI UNION GROUP (nvdr)	300,000.00	178,226.35	1.10
SGD	UOL GROUP	50,000.00	222,778.66	1.38
AUD	WESFARMERS	18,500.00	589,871.36	3.64
AUD	WOODSIDE PETROLEUM	16,500.00	329,495.64	2.04
HKD	XINJIANG GOLDWI SCIENCE % TECHNOLOGY - H-	150,000.00	214,657.93	1.33
HKD	ZHEJIANG EXPRESSWAY -H-	270,000.00	289,614.16	1.79
Share	es (and equity-type securities) rities listed on a stock exchange or other organise	-ddt	15,107,863.78	93.58
	es (and equity-type securities)	ed markets:	15,107,863.78	93.58
Secu	rities listed on a stock exchange or other organise	ed markets: Inves	tment funds	
Fund	units (Open-End)			
USD	DB X-TRACKERS S&P CNX NIFTY -1C-	2,500.00	299,958.05	1.86
USD	ISHARES INDIA 50 ETF	9,000.00	242,100.00	1.50
Fund	units (Open-End)		542,058.05	3.36
Secu	rities listed on a stock exchange or other organise tment funds	ed markets:	542,058.05	3.36
Total	of Portfolio		15,649,921.83	96.94
Cash :	at banks and at brokers		461,642.49	2.86
Other	net assets		32,381.73	0.20
Total	net assets		16,143,946.05	100.00
_				

Technical Data

		Valoren	ISIN	Management Fee	Total Expense Ratio
B -Capitalisation	EUR	25290511	LU1103912694	1.60%	2.39%
DB -Capitalisation	EUR	25673923	LU1120400996	0.00%	0.09%
UB -Capitalisation	EUR	26124853	LU1138991747	0.95%	1.73%
UBH -Capitalisation	CHF	26383488	LU1144422919	0.95%	1.69%
UBH -Capitalisation	GBP	26124890	LU1138998676	0.95%	1.74%

There is no management fee for DB-shares.

Fund Performance

		YTD	Since Inception	2015
B -Capitalisation	EUR	-7.58%	6.10%	8.71%
DB -Capitalisation	EUR	-7.09%	9.57%	11.31%
UB -Capitalisation	EUR	-7.48%	-6.00%	/
UBH -Capitalisation	CHF	-7.58%	-7.30%	/
UBH -Capitalisation	GBP	-7.62%	-6.70%	/

Notes

Forward foreign exchange contracts

Purchases		Sales		Maturity	Valuation
Counterparty					(in EUR)
GBP	9,203.60	EUR	-11,857.96	15.06.2016	-271.82
Credit Suisse Zürich					
CHF	79,398.40	EUR	-72,616.38	15.06.2016	219.97
Credit Suisse Zürich					
Net unrealised loss	on forward foreign ex	change contracts			-51.85

Statement of Net Assets in EUR and Fund Evolution

	31.03.2016
Assets	
Investments in securities at market value	23,862,564.01
Cash at banks and at brokers	299,513.06
Income receivable	48,514.23
	24,210,591.30
Liabilities	
Due to banks and to brokers	14.45
Provisions for accrued expenses	6,380.88
Net unrealised loss on forward foreign exchange contracts	51.85
	6,447.18
Net assets	24,204,144.12

Fund Evolution		31.03.2016	30.09.2015
Total net assets	EUR	24,204,144.12	24,539,192.06
Net asset value per share			
B -Capitalisation	EUR	10.61	10.94
DB -Capitalisation	EUR	1,095.69	1,116.29
UB -Capitalisation	EUR	9.40	9.66
UBH -Capitalisation	CHF	9.27	9.57
UBH -Capitalisation	GBP	9.33	9.61

Number of shares outstanding		at the end of the period	at the beginning of the period	Number of shares issued	Number of shares redeemed
B -Capitalisation	EUR	144,315.006	146,316.139	34,898.587	36,899.720
DB -Capitalisation	EUR	20,000.000	20,000.000	0.000	0.000
UB -Capitalisation	EUR	71,713.783	54,241.200	20,322.583	2,850.000
UBH -Capitalisation	CHF	8,638.515	8,638.515	0.000	0.000
UBH -Capitalisation	GBP	990.988	990.988	0.000	0.000

Statement of Operations / Changes in Net Assets in EUR

For the period from 01.10.2015 to 31.03.2016

Net assets at the beginning of the period	24,539,192.06
Income	
Dividends (net)	252,287.24
Securities lending income	84.83
	252,372.07
Expenses	
Management fee	17,142.39
Custodian and safe custody fees	5,682.41
Administration expenses	6,957.92
Printing and publication expenses	3,033.80
Interest and bank charges	1,280.30
Audit, control, legal, representative bank and other expenses	5,130.61
"Taxe d'abonnement"	632.17
	39,859.60
Net income (loss)	212,512.47
Realised gain (loss)	
Net realised gain (loss) on sales of investments	-571,171.68
Net realised gain (loss) on forward foreign exchange contracts	1,713.48
Net realised gain (loss) on foreign exchange	-4,153.60
	-573,611.80
Net realised gain (loss)	-361,099.33
Change in net unrealised appreciation (depreciation)	
Change in net unrealised appreciation (depreciation) on investments	-171,904.11
Change in net unrealised appreciation (depreciation) on forward foreign exchange contracts	-591.04
	-172,495.15
Net increase (decrease) in net assets as a result of operations	-533,594.48
Subscriptions / Redemptions	
Subscriptions	625,121.75
Redemptions	-426,575.21
	198,546.54
Net assets at the end of the period	24,204,144.12
	,= v .,

Breakdown by Country and Economic Sector of the Investments in Securities Statement of Investments in Securities and Other Net Assets

Breakdown by Country

United Kingdom	26.80
Germany	18.80
France	15.14
Switzerland	14.67
Belgium	4.83
Sweden	4.49
Norway	4.20
Denmark	3.61
Spain	2.40
Italy	1.93
Finland	1.18
Netherlands	0.54
Total	98.59

Breakdown by Economic Sector

Total	98.59
Aeronautic and astronautic industry	0.34
Financial, investment and other div. companies	0.54
Building materials and building industry	0.78
Miscellaneous consumer goods	1.00
Miscellaneous services	1.25
Mechanical engineering and industrial equipment	1.28
Precious metals and precious stones	1.47
Computer hardware and networking	1.48
Lodging and catering industry, leisure facilities	2.00
Telecommunication	2.00
Forestry, paper and forest products	2.61
Rubber and tires	3.15
Vehicles	3.17
Agriculture and fishery	3.26
Traffic and transportation	3.66
Petroleum	3.76
Energy and water supply	3.98
Miscellaneous trading companies	3.98
Food and soft drinks	4.38
Chemicals	4.88
Banks and other credit institutions	7.44
Retailing, department stores	9.39
Insurance companies	9.69
Electrical appliances and components	10.65
Pharmaceuticals, cosmetics and medical products	12.45

Statement of Investments in Securities and Other Net Assets

	Description	Quantity / Nominal	Valuation (in EUR)	% of net assets
Secu	rities listed on a stock exchange or other organ	ised markets: Share	s (and equity-type	securities)
Share	es (and equity-type securities)			
EUR	ALLIANZ SE (reg. shares) (restricted)	1,839.00	262,885.05	1.09
DKK	A.P. MOELLER - MAERSK -B-	120.00	138,356.84	0.5
EUR	ATOS	5,000.00	357,900.00	1.48
EUR	AXA	22,830.00	472,352.70	1.98
GBP	BARCLAYS	235,391.00	445,338.34	1.84
EUR	BASF (reg. shares)	7,600.00	503,880.00	2.08
EUR	BAYER (reg. shares)	5,100.00	526,830.00	2.18
EUR	BMW	2,420.00	195,294.00	0.8
EUR	BNP PARIBAS -A-	17,537.00	775,661.51	3.20
GBP	BP	62,318.00	275,217.86	1.1
GBP	CAPITA	23,089.00	303,446.28	1.2
DKK	CHRISTIAN HANSEN HOLDING	3,500.00	206,515.17	0.8
EUR	COLRUYT	11,240.00	575,488.00	2.3
EUR	CONTINENTAL	2,384.00	476,800.00	1.9
EUR	DAIMLER (reg. shares)	4,303.00	289,893.11	1.20
EUR	DELHAIZE GROUP	6,467.00	593,347.25	2.4
GBP	DOMINO'S PIZZA UK & IRL	38,035.00	483,562.84	2.0
GBP	EASYJET	18,000.00	344,857.16	1.49
CHF	EMMI (reg. shares)	1,775.00	854,765.18	3.5
EUR	ENEL	119,593.00	466,173.51	1.9
EUR	FRESENIUS	9.841.00	631,890.61	2.6
GBP	GKN	85,071.00	309,875.83	1.2
FUR	HENKEL (pref. shares)	2,500.00	242,250.00	1.00
SEK	HOLMEN -B-	12,000.00	345,269.54	1.4
EUR	INDUSTRIA DE DISENO TEXTIL INDITEX	14,530.00	429,579.45	1.7
EUR	IPSEN	9.150.00	461.800.50	1.9
GBP	J. SAINSBURY	194,000.00	676,069.87	2.7
GBP	JOHNSON MATTHEY	10,294.00	356.268.35	1.4
CHE	LONZA GROUP (reg. shares)	1.000.00	149,095.07	0.6
GBP	LOOKERS	140,000.00	279,699.82	1.10
GBP	MAN GROUP	225,458.00	433,655.11	1.79
FUR	MAPFRE (reg. shares)	80,000.00	151,920.00	0.6
NOK	MARINE HARVEST	24,951.00	337,515.52	1.3
GBP				0.3
EUR	MEGGITT	16,000.00 3,178.00	82,053.35 285,797.54	1.18
CHF	MICHELIN (reg. shares)	-,	921.349.37	3.8
	NOVARTIS (reg. shares)	14,425.00		
GBP GBP	OLD MUTUAL REDROW	341,071.00	830,684.37	3.4
		37,300.00	189,263.92	0.7
CHF	ROCHE HOLDINGS (cert. shares)	4,600.00	997,773.20	4.1
GBP	ROYAL DUTCH SHELL -A-	15,201.00	322,866.67	1.3
GBP	ROYAL MAIL	66,500.00	403,185.34	1.6
EUR	SAFRAN	6,800.00	418,064.00	1.73
NOK	SALMAR	21,000.00	452,283.70	1.8
EUR	SAP SE	8,600.00	611,460.00	2.5
DKK	SCHOUW & CO	9,673.00	531,019.82	2.1
EUR	SIEMENS (reg. shares)	8,650.00	805,747.50	3.3
EUR	SOCIETE GENERALE PARIS -A-	17,877.00	580,644.96	2.4
GBP	SSE	26,400.00	496,800.15	2.0
CHF	SWISS REINSURANCE	5,054.00	411,730.22	1.7
SEK	TELEFON LM ERICSSON -B-	84,085.00	739,998.97	3.0
NOK	TELENOR	16,000.00	227,298.29	0.9
EUR	TKH GROUP	3,500.00	131,705.00	0.5
EUR	TOTAL	7,790.00	312,067.40	1.2
EUR	UPM-KYMMENE	17,993.00	286,448.56	1.1
GBP	VODAFONE GROUP	91,908.00	256,417.36	1.0
CHF	ZURICH INSURANCE GROUP (reg. shares)	1,048.00	214,449.85	0.8
Share	es (and equity-type securities)		23,862,564.01	98.5
Secu	rities listed on a stock exchange or other organ	ised markets:	23,862,564.01	98.5
	es (and equity-type securities)			
	of Portfolio		23,862,564.01	98.5
	at banks and at brokers		299,513.06	1.2
	b banks and to brokers		-14.45	
	net assets		42,081.50	0.1
Total	net assets		24,204,144.12	100.00

Technical Data

		Valoren	ISIN	Management Fee	Total Expense Ratio
B -Capitalisation	USD	1258035	LU0130190969	1.92%	2.23%
EB -Capitalisation	USD	23789980	LU1038189665	0.90%	1.19%
IB -Capitalisation	USD	1258038	LU0130191181	0.90%	1.21%
UB -Capitalisation	USD	26378225	LU1144413843	1.15%	1.53%
BH -Capitalisation	EUR	2388468	LU0240068329	1.92%	2.23%
IBH -Capitalisation	EUR	11065084	LU0491223573	0.90%	1.24%
UBH -Capitalisation	EUR	26378226	LU1144413926	1.15%	1.47%

 $As at 16.12.2015 \ Credit \ Suisse \ (Lux) \ Biotechnology \ Equity \ Fund \ has been \ renamed \ in \ Credit \ Suisse \ (Lux) \ Global \ Biotech \ Innovators \ Equity \ Fund.$

Fund Performance

		YTD	Since Inception	2015	2014	2013
B -Capitalisation	USD	-22.83%	/	9.40%	31.12%	61.10%
EB -Capitalisation	USD	-22.63%	1.21%	10.56%	/	/
IB -Capitalisation	USD	-22.63%	/	10.52%	32.47%	62.75%
UB -Capitalisation	USD	-22.68%	-23.92%	/	/	/
BH -Capitalisation	EUR	-22.91%	/	9.36%	30.79%	60.12%
IBH -Capitalisation	EUR	-22.71%	-3.90%	10.48%	/	/
UBH -Capitalisation	EUR	-22.77%	-23.85%	/	/	/

Notes

Forward foreign exchange contracts

Purchases		Sales		Maturity	Valuation
Counterparty					(in USD)
EUR	13,564,609.48	USD	-15,124,485.31	15.06.2016	370,327.40
Credit Suisse Z	?ürich				
USD	597,185.59	EUR	-537,339.90	15.06.2016	-16,576.20
Credit Suisse Z	?ürich				
EUR	269,456.14	USD	-302,995.08	15.06.2016	4,803.86
State Street Ba	ank And Trust CY (London)				
EUR	283,955.15	USD	-318,793.04	15.06.2016	5,568.08
Credit Suisse Z	Zürich				
USD	493,472.95	EUR	-441,450.25	15.06.2016	-10,768.38
Credit Suisse Z	Zürich				
EUR	15,554.70	USD	-17,751.29	15.06.2016	16.80
State Street Ba	ank And Trust CY (London)				
Net unrealised	d gain on forward foreign e	xchange contracts	3		353,371.56

Statement of Net Assets in USD and Fund Evolution

	31.03.2016
Assets	
Investments in securities at market value	164,462,868.57
Cash at banks and at brokers	1,777,096.29
Subscriptions receivable	1,509,963.22
Income receivable	8,231.84
Net unrealised gain on forward foreign exchange contracts	353,371.56
	168,111,531.48
Liabilities	
Redemptions payable	1,410,665.24
Provisions for accrued expenses	294,280.31
Other liabilities	60.81
	1,705,006.36
Net assets	166,406,525.12

Fund Evolution		31.03.2016	30.09.2015	30.09.2014
Total net assets	USD	166,406,525.12	215,955,957.36	204,929,339.50
Net asset value per share				
B -Capitalisation	USD	351.07	416.84	372.17
EB -Capitalisation	USD	1,012.08	1,195.31	1,056.04
IB -Capitalisation	USD	382.71	452.09	399.55
UB -Capitalisation	USD	76.08	89.99	/
BH -Capitalisation	EUR	236.05	280.72	250.60
IBH -Capitalisation	EUR	961.00	1,136.76	1,005.78
UBH -Capitalisation	EUR	76.15	90.16	/

Number of shares outstanding		at the end of the period	at the beginning of the period	Number of shares issued	Number of shares redeemed
B -Capitalisation	USD	377,530.351	433,509.323	20,353.267	76,332.239
EB -Capitalisation	USD	4,017.417	5,295.651	716.000	1,994.234
IB -Capitalisation	USD	12,675.702	15,792.137	2,281.000	5,397.435
UB -Capitalisation	USD	121,936.472	10,687.374	112,567.896	1,318.798
BH -Capitalisation	EUR	48,220.585	61,099.055	7,457.752	20,336.222
IBH -Capitalisation	EUR	2,105.453	1,015.802	1,402.554	312.903
UBH -Capitalisation	EUR	2,448.711	3,858.920	539.791	1,950.000

Statement of Operations / Changes in Net Assets in USD

For the period from 01.10.2015 to 31.03.2016

Net assets at the beginning of the period	215,955,957.36
Income	
Dividends (net)	264,699.46
Securities lending income	21,330.88
	286,030.34
Expenses	
Management fee	1,846,324.72
Custodian and safe custody fees	45,328.60
Administration expenses	100,859.22
Printing and publication expenses	26,545.57
Interest and bank charges	54.78
Audit, control, legal, representative bank and other expenses	158,003.01
"Taxe d'abonnement"	49,603.19
	2,226,719.09
Net income (loss)	-1,940,688.75
Realised gain (loss)	
Net realised gain (loss) on sales of investments	13,719,576.72
Net realised gain (loss) on forward foreign exchange contracts	-826,893.40
Net realised gain (loss) on foreign exchange	116,849.72
	13,009,533.04
Net realised gain (loss)	11,068,844.29
Change in net unrealised appreciation (depreciation)	
Change in net unrealised appreciation (depreciation) on investments	-44,296,302.01
Change in net unrealised appreciation (depreciation) on forward foreign exchange contracts	719,848.19
	-43,576,453.82
Net increase (decrease) in net assets as a result of operations	-32,507,609.53
Subscriptions / Redemptions	
Subscriptions	24,108,096.43
Redemptions	-41,149,919.14
	-17,041,822.71

Breakdown by Country and Economic Sector of the Investments in Securities Statement of Investments in Securities and Other Net Assets

Breakdown by Country

USA	84.47
Switzerland	5.66
Denmark	4.77
Ireland	2.32
Luxembourg	0.96
Cayman Islands	0.43
Canada	0.22
Total	98.83

Breakdown by Economic Sector

Biotechnology	52.18
Pharmaceuticals, cosmetics and medical products	38.47
Financial, investment and other div. companies	5.21
Chemicals	2.88
Internet, software and IT services	0.09
Total	98.83

Statement of Investments in Securities and Other Net Assets

CHF ACTELION (reg. shares)		Description	Quantity / Nominal	Valuation (in USD)	% of ne asset
SED ACCELERON PHARMA 50,000.00 1,319,500.00 0 OPT ACTELION (reg. shares) 29,112.00 3,918,374.70 0 SED ACGERTON PHARMACEUTICALS 20,000.00 74,000.00 0 ACGERTON PHARMACEUTICALS 30,000.00 1,1591,850.00 0 ACGERTON PHARMACEUTICALS 52,752.00 7,344,133.44 ACGERTON PHARMACEUTICALS 50,000.00 3,344,133.44 ACGERTON PHARMACEUTICALS 50,000.00 3,344,133.44 ACGERTON PHARMACEUTICALS 50,000.00 1,045,310.00 6 ACGERTON PHARMACEUTICALS 50,000.00 1,045,310.00 6 ACGERTON PHARMACEUTICALS 50,000.00 1,045,310.00 6 ACGERTON PHARMACEUTICALS 20,000.00 1,045,310.00 6 ACGERTON PHARMACEUTICALS 40,000.00 707,486.83 0 ACGERTON PHARMACEUTICAL 85,444.00 7,000.00 707,486.83 0 ACGERTON PHARMACEUTICAL 85,444.00 7,000.00 707,486.83 0 ACGERTON PHARMACEUTICAL 85,444.00 7,000.00 1,000,500.00 0 ACGERTON PHARMACEUTICAL 85,444.00 7,000,444.11 1 ACGERTON PHARMACEUTICAL 85,444.00 7,000,444.11 1 ACGERTON PHARMACEUTICAL 85,444.00 7,000,444.11 1 ACGERTON PHARMACEUTICAL 81,000,000 364,600.00 0 ACGERTON PHARMACEUTICALS 1,000,000 3,000,600.00 0 ACGERTON PHARMACEUTICALS 1,000,000 3,000,600.00 0 ACGERTON PHARMACEUTICALS 1,000,000 4,76,600.00 0 ACGERTON PHARMA	Secur	rities listed on a stock exchange or other organ	nised markets: Shar	es (and equity-type	securities
Color Colo	Share	es (and equity-type securities)			
J.S.D. AGEGRION PHARMACEUTICALS 30,000.00 74,000.00 0.9					0.7
J.S.D. AGIOS PHARMACEUTICALS 30,000.00 1,919,850.00 0 1,919,					2.3
JSD ALDER BIOPHARMACEUTICALS					0.0
J.S.D. ALEXION PHARMACEUTICALS 52,752.00 7,344,133.44 4,325 ALEXIONS PHARMACEUTICALS 65,000.00 2,223.80.00 1,005.310.00 1,0					0.7
SED ALIVERMES 65,000					4.4
J.S.D. ALNYLAM PHARMACEUTICALS					1.3
JSD AMGEN 67,000.00 10,045,310.00 6					1.8
J.SD ANACOR PHARMACELITICALS 2,000,000 1,069,000,000 0 0,000,000 0 0,000,000					6.0
USD ARROWHEAD RESEARCH 30,000.00 144,600.00 0.00	USD	ANACOR PHARMACEUTICALS		1,069,000.00	0.6
Chef	JSD		88,000.00		0.2
SIND THERAPEUTICS					0.0
USD BIOGEN					0.4
USD BIOLIFE SOLUTIONS 110,274,00 202,904.16 0 0 0 0 0 0 0 0 0					0.0
ISBN BIOMARIN PHARMACEUTICAL 85,444.00 7,047.421.12 44 425.00 54,000.00 1,062,500.00 1,062,500.00 1,062,500.00 1,062,500.00 1,062,500.00 1,062,500.00 1,062,500.00 1,062,500.00 1,062,500.00 1,062,500.00 1,060,000 2,040,000.00 1,060,000 2,040,000.00 1,000.00 2,000,600.00 1,000.00 2,000,600.00 1,000.00					7.3
USD BLUEBIRD BIO 25,000.00 1,082,500.00 0					0.1 4.2
USD CELGENE 122,276.00 12,338,694.84 7, 70,000 264,600.00 0, 264,600.00					0.6
USD CELLDEX THERAPEUTICS 70,000,00 28,46,000,00 0 1 USD CEPHEID 60,000,00 2,001,600,00 0 1 USD CEPHEID 60,000,00 2,001,600,00 0 0 CHF COSMO PHARMACEUTICALS 10,000,00 884,000,00 0 CHF COSMO PHARMACEUTICALS 10,000,00 884,000,00 0 CHF COSMO PHARMACEUTICALS 2,439,00 6,560,91 0 USD ESPERION THERAPEUTICS 27,000,00 456,570,00 0 USD ESPERION THERAPEUTICS 6,000,00 243,780,00 0 USD GALECTIN THERAPEUTICS 30,000,00 429,900,00 0 USD GALECTIN THERAPEUTICS 30,000,00 429,900,00 0 DKK GENMAB 23,155,00 3,209,874,11 1 USD GILEAD SCIENCES 136,484,00 12,445,560,24 7 USD HALOZYME THERAPEUTICS 194,000,00 1,837,180,00 1 USD INSURE THERAPEUTICS 194,000,00 1,837,180,00 1 USD INSURE THERAPEUTICS 194,000,00 1,837,180,00 1 USD INFINITY PHARMACEUTICALS 90,000,00 474,300,00 0 USD INFINITY PHARMACEUTICALS 90,000,00 474,300,00 0 USD INFINITY PHARMACEUTICALS 1,800,00 2,800,646,00 1 USD INFINITY PHARMACEUTICALS 1,1000,00 2,741,550,00 1 USD INSURE THERAPEUTICS 30,000,00 2,741,550,00 1 USD INSURE THERAPEUTICS 104,000 3,248,100,00 1 USD INSURA THERAPEUTICS 104,000 3,274,1750,00 1 USD INSURA THERAPEUTICS 104,000 3,770,260 0 USD MEDIVATION 140,000,00 6,437,200,00 3 USD MEDIVATION 140,000,00 837,000,00 1 USD MEDIVATION 140,000,00 1,427,800,00 1 USD MEDIVATION 140,000,00 9,200,000,00 1 USD MEDIVATION 140,000,00 9,370,262,00 0 USD MEDIVAT					7.4
USD CEPHEID 60,000.00 2,001,600.00 1					0.1
USD CLOVIS ONCOLOGY					1.2
CHF COSMO PHARMACEUTICALS 1,000.00 1,596,675.07 0,000.00 1,596,675.07 0,000.00 1,596,675.07 0,000.00 1,596,675.07 0,000.00 1,000.00 1,000.00 1,000.00 0,000.00 1,000.00 0,000.00 1,000.00 0,000.00 1,000.00 0,000.					0.5
USD EPIRUS BIOPHARMACEUTICALS EPIRUS EIPRINGT THERAPEUTICS 27,000.00 456,570.00 00 USD GALECTIN THERAPEUTICS 6,000.00 243,780.00 00 USD GALECTIN THERAPEUTICS 30,000.00 429,900.00 01 USD GALECTIN THERAPEUTICS 30,000.00 429,900.00 02,209.0074.11 10 USD GALECTIN THERAPEUTICS 136,484.00 12,445,580.24 7 USD HALOZYME THERAPEUTICS 194,000.00 1,837,180.00 1359 ILLUMINA 36,600.00 5,933,228.00 30 USD INCYTE 90,000.00 6,522,300.00 30 USD INFINITY PHARMACEUTICALS 90,000.00 474,300.00 10 USD INFINITY PHARMACEUTICALS 90,000.00 474,300.00 10 USD INTERCEPT PHARMACEUTICALS 11,800.00 12,248,100.00 11,427,000.00 13,248,100.00 13,248,100.00 14,000.00 14,000.00 14,000.00 14,000.00 15,000					0.9
USD FIVE PRIME THERAPEUTICS 6,000.00 243,780.00 0	USD	EPIRUS BIOPHARMACEUTICALS			0.0
USD GALECTIN THERAPEUTICS 30,000.00 42,900.00 0 DORK GENMAB 23,125.00 3,209,874.11 1 DUSD GILEAD SCIENCES 135,484.00 12,445,560.24 7 USD HALOZYME THERAPEUTICS 194,000.00 1,837,180.00 1 USD ILLUMINA 36,600.00 5,933,226.00 3 USD INFINITY PHARMACEUTICALS 90,000.00 474,300.00 0 USD INFINITY PHARMACEUTICALS 90,000.00 474,300.00 1 USD INTERCEPT PHARMACEUTICALS 21,800.00 2,800,646.00 1 USD INTERCEPT PHARMACEUTICALS 21,800.00 2,741,550.00 1 USD JAZZ PHARMACEUTICALS 21,000.00 2,741,550.00 1 USD JAZZ PHARMACEUTICALS 21,000.00 2,741,550.00 1 USD JUNO THERAPEUTICS 30,000.00 1,142,700.00 0 USD MERRIMACK PHARMACEUTICALS 100,000.00 837,000.00 1 USD MYRIAD GENETICS 103,400.00 3870,282.00 2 USD MYRIAD GENETICS 160,000.00 2,200,000.00 1 USD MYRIAD GENETICS 160,000.00 2,200,000.00 1 USD MYRIAD GENETICS 160,000.00 2,200,000.00 1 USD MEUROCRINE BIOSCIENCES 85,000.00 3,361,750.00 2 USD MYRIAD GENETICS 160,000.00 2,200,000.00 1 USD NEUROCRINE BIOSCIENCES 85,000.00 3,361,750.00 2 USD MYRIAD GENETICS 160,000.00 1,4726,632.47 2 USD ONCOMED PHARMACEUTICALS 36,500.00 3,99,105.00 0 USD PROTHENA CORPORATION 39,600.00 1,629,936.00 0 USD PROTHENA CORPORATION 39,600.00 1,414,800.00 0 USD REGENERON PHARMACEUTICALS 23,000.00 2526,660.00 0 USD PLANG BIOTECHNOLOGY 18,000.00 228,360.00 0 USD PLANG BIOTECHNOLOGY 18,000.00 2528,660.00 0 USD SEATTLE GENETICS 80,000.00 2,807,200.00 1 USD SEGENERON PHARMACEUTICALS 70,000.00 3,629,170.00 0 USD SEATTLE GENETICS 80,000.00 3,629,170.00 0 USD SEATTLE GENETICS 80,000.00 3,629,171.00 0 USD SEATTLE GENETICS 80,000.00 3,629,171.00 0 USD SEATTLE GENETICS 80,000.00 3,628,360.00 0 USD SEATTLE GENETICS 80,000.00 3,628,537.5 0 USD SECURITIES IISED ON A \$1,747,400 709,023.20 0 USD USD SECURE ON \$1,765.00 \$1,765.00 \$1,765.00 \$1,765.00 \$1,777,090.29 0 USD LITERARY ANCHERICALS 70,000.00 \$1,765.00 \$1,777,090.29 1 USD ALPHAVAX (pref. shares) -B- 453,000.00 \$4,765.00 \$1,777,09					0.2
DKK GENMAB					0.1
USD GILEAD SCIENCES 135,484,00 12,445,660.24 7					0.0
USD HALOZYME THERAPEUTICS 194,000.00 1,837,180.00 1 USD ILLUMINA 36,600.00 5,933,226.00 3 USD INFINITY PHARMACEUTICALS 90,000.00 4,74,300.00 0 USD INTERCEPT PHARMACEUTICALS 21,800.00 2,800,646.00 1 USD INTERCEPT PHARMACEUTICALS 21,800.00 2,800,646.00 1 USD INTERCEPT PHARMACEUTICALS 21,800.00 2,800,646.00 1 USD JAZZ PHARMACEUTICALS 21,000.00 2,741,550.00 1 USD JAZZ PHARMACEUTICALS 21,000.00 2,741,550.00 1 USD JAZZ PHARMACEUTICALS 21,000.00 2,741,550.00 1 USD MEDIATION 140,000.00 6,437,200.00 3 USD MERRIMACK PHARMACEUTICALS 100,000.00 337,000.00 0 USD MYRIAD GENETICS 103,400.00 3,870,262.00 2 USD MERRIMACK PHARMACEUTICALS 100,000.00 387,000.00 0 USD MYRIAD GENETICS 160,000.00 3,831,750.00 2 USD NEUROCRINE BIOSCIENCES 85,000.00 3,361,750.00 2 USD NEUROCRINE BIOSCIENCES 87,000.00 4,726,632.47 2 USD ONCOMED PHARMACEUTICALS 36,500.00 369,015.00 0 USD PROTHENA CORPORATION 39,600.00 1,629,396.00 0 USD PROTHENA CORPORATION 39,600.00 1,629,396.00 0 USD PROTHENA CORPORATION 39,600.00 1,629,396.00 0 USD PROTHENA CORPORATION 39,600.00 1,414,800.00 0 USD REGENERON PHARMACEUTICALS 23,000.00 \$2,200,120.00 4 USD REGULUS THERAPEUTIC 60,000.00 141,4800.00 0 USD REGULUS THERAPEUTIC 60,000.00 141,4800.00 0 USD SEATTLE GENETICS 80,000.00 2,807,200.00 1 USD SEQUENOM 180,000.00 258,3600.00 0 USD SECULENOM 180,000.00 558,860.00 0 USD UNITED THERAPEUTICS 18,000.00 2,005,740.00 1 USD THERAVANCE BIO 37,714.00 709,023.20 0 USD ULTRAGENYX PHARMACEUTICAL 15,000.00 499,660.00 0 USD UNITED THERAPEUTICS 18,000.00 2,005,740.00 1 USD THERAVANCE BIO 37,714.00 709,023.20 0 USD ULTRAGENYX PHARMACEUTICAL 15,000.00 499,660.00 0 USD UNITED THERAPEUTICS 18,000.00 2,005,740.00 1 USD VERTEX PHARMACEUTICAL 15,000.00 499,660.00 0 USD UNITED THERAPEUTICS 18,000.00 2,005,740.00 1 USD VERTEX PHARMACEUTICAL 15,000.00 19,425.00 0 USD VERTEX PHARMACEUTICAL 15,000.00 499,660.00 0 USD VERTEX PHARMACEUTICAL 15,000.00 19,425.00 0 USD VERTEX PHARMACEUTI					1.9
USD ILLUMINA 36,600.00 5,933,226.00 3 3 1 1 1 1 1 1 1 1					7.4
USD INCYTE					1.1
USD INFINITY PHARMACEUTICALS 90,000.00 474,300.00 0 USD INTERCEPT PHARMACEUTICALS 21,800.00 2,800,646.00 1 USD IONS PHARMACEUTICALS 80,000.00 3,248,100.00 1 USD JAZZ PHARMACEUTICALS 21,000.00 2,741,550.00 1 USD JAZZ PHARMACEUTICALS 21,000.00 2,741,550.00 1 USD MEDIVATION 140,000.00 6,437,200.00 0 USD MEDIVATION 140,000.00 837,000.00 3 USD MERIMACK PHARMACEUTICALS 100,000.00 837,000.00 0 USD MERIMACK PHARMACEUTICALS 100,000.00 3,870,262.00 2 USD NEKTAR THERAPEUTICS 103,400.00 3,870,262.00 2 USD NEKTAR THERAPEUTICS 160,000.00 2,200,000.00 1 USD NEWO-CONTRIBE BIOSCIENCES 85,000.00 3,861,750.00 2 USD NOCOMED PHARMACEUTICALS 36,500.00 3,861,750.00 0 USD NOCOMED PHARMACEUTICALS 36,500.00 369,015.00 0 USD PROTHENA CORPORATION 39,600.00 1,529,936.00 0 USD PUMA BIOTECHNOLOGY 18,000.00 1,529,936.00 0 USD PLIMA BIOTECHNOLOGY 18,000.00 1,229,936.00 0 USD REGULUS THERAPEUTIC 60,000.00 4,174,800.00 0 USD REGULUS THERAPEUTIC 60,000.00 4,15,800.00 0 USD SANGAMO BIOSCIENCES 120,000.00 726,000.00 0 USD SEQUENOM 180,000.00 2,807,200.00 0 USD SECUENOM 180,000.00 2,807,000.00 0 USD SECUENOM 180,000.00 2,807,000.00 0 USD SECUENOM 180,000.00 2,807,700.00 0 USD SEATTLE GENETICS 80,000.00 2,807,700.00 1 USD THERAVANCE BIO 37,714.00 709,023.20 0 USD THERAVANCE BIO 37,714.00 709,023.20 0 USD ULTRAGENTYX PHARMACEUTICAL 15,000.00 249,650.00 0 USD THERAVANCE BIO 37,714.00 709,023.20 0 USD ULTRAGENTYX PHARMACEUTICAL 15,000.00 249,650.00 0 USD THERAVANCE BIO 37,714.00 709,023.20 0 USD ULTRAGENTYX PHARMACEUTICAL 15,000.00 149,650.00 0 USD THERAVANCE BIO 37,714.00 709,023.20 0 USD VERTEX PHARMACEUTICAL 15,000.00 149,650.00 0 USD THERAVANCE BIO 37,714.00 709,023.20 0 USD VERTEX PHARMACEUTICAL 15,000.00 149,650.00 0 USD THERAVANCE BIO 17,765.00 4,792,113.73 2 USD VERTEX PHARMACEUTICAL 15,000.00 19,425.00 0 USD					3.5 3.9
USD INTERCEPT PHARMACEUTICALS 21,800.00 2,800,646.00 1 1 1 1 1 1 1 1 1					0.2
USD IONIS PHARMACEUTICALS 80,200.00 3,248,100.00 1 USD JAZZ PHARMACEUTICALS 21,000.00 2,741,550.00 1 USD JUND THERAPEUTICS 30,000.00 1,142,700.00 3 USD MEDIVATION 140,000.00 6,437,200.00 3 USD MERRIMACK PHARMACEUTICALS 100,000.00 387,000.00 0 USD MYRIAD GENETICS 160,000.00 3,870,262.00 2 USD NEKTAR THERAPEUTICS 160,000.00 2,200,000.00 0 USD NEUROCRINE BIOSCIENCES 85,000.00 3,361,750.00 2 USD NEUROCRINE BIOSCIENCES 85,000.00 3,691,15.00 2 USD PROTHEINA CORPORATION 39,600.00 1,629,936.00 0 USD PROTHEINA CORPORATION 39,600.00 1,629,936.00 0 USD RADIUS HEALTH 45,000.00 528,660.00 0 USD RADIUS HEALTH 45,000.00 1,414,800.00 0 USD REGENERON PHARMACEUTIC					1.6
USD JAZZ PHARMACEUTICALS 21,000.00 2,741,550.00 1 USD JUNO THERAPPEUTICS 30,000.00 1,142,700.00 0 USD MEDIVATION 140,000.00 6,437,200.00 3 USD MERRIMACK PHARMACEUTICALS 100,000.00 837,000.00 0 USD MYRIAD GENETICS 103,400.00 3,870,262.00 2 USD NEKTAR THERAPEUTICS 160,000.00 2,200,000.00 1 USD NEUROCRINE BIOSCIENCES 85,000.00 3,361,750.00 1 USD NEUROCRINE BIOSCIENCES 85,000.00 3,361,750.00 1 USD NOCOMED PHARMACEUTICALS 36,500.00 369,015.00 0 USD PROTHENA CORPORATION 39,600.00 1,629,936.00 0 USD PROTHENA CORPORATION 39,600.00 1,629,936.00 0 USD PUMA BIOTECHNOLOGY 18,000.00 528,660.00 0 USD REGIOLUS THERAPEUTICS 23,000.00 8,290,120.00 4 USD REGIOLUS THERAPEUTIC 60,000.00 1,414,800.00 0 USD SANGAMO BIOSCIENCES 120,000.00 726,000.00 0 USD SANGAMO BIOSCIENCES 120,000.00 726,000.00 0 USD SANGAMO BIOSCIENCES 120,000.00 2,807,200.00 1 USD SEQUENOM 180,000.00 2,807,200.00 0 USD SECUENOM 180,000.00 528,360.00 0 USD THERAVANCE BIO 37,714.00 709,023.20 0 USD THERAVANCE BIO 37,714.00 709,023.20 0 USD THERAVANCE BIO 37,714.00 709,023.20 0 USD ULTRAGENTY PHARMACEUTICAL 15,000.00 249,650.00 0 USD ULTRAGENTY PHARMACEUTICAL 15,000.00 249,650.00 0 USD ULTRAGENTY PHARMACEUTICAL 15,000.00 1,564,300.00 1 USD VERTEX PHARMACEUTICAL 15,000.00 249,650.00 0 USD ULTRAGENTY PHARMACEUTICAL 15,000.00 149,425.00 0 USD VERTEX PHARMACEUTICAL 15,000.00 149,425.00 0 USD VERTEX PHARMACEUTICAL 17,000.00 19,425.00 0 USD VERTEX PHARMACEUTIC					1.9
USD JUNO THERAPEUTICS 30,000.00 1,142,770.00 0 USD MEDIVATION 140,000.00 6,437,200.00 3 USD MERIMACK PHARMACEUTICALS 100,000.00 837,000.00 0 USD MERIMACK PHARMACEUTICALS 103,400.00 3,870,262.00 2 USD NEKTAR THERAPEUTICS 160,000.00 2,200,000.00 1 USD NEUROCRINE BIOSCIENCES 85,000.00 3,361,750.00 2 DKK NOVO-NORDISK -B 87,000.00 4,726,632.47 2 USD ONCOMED PHARMACEUTICALS 36,500.00 369,015.00 0 USD PUMA BIOTECHNOLOGY 18,000.00 1,629,936.00 0 USD PUMA BIOTECHNOLOGY 18,000.00 528,660.00 0 USD PUMA BIOTECHNOLOGY 18,000.00 1,414,800.00 0 USD REGENERON PHARMACEUTICALS 23,000.00 1,414,800.00 0 USD REGENERON PHARMACEUTICALS 23,000.00 3,290,120.00 4 USD REGENERON SEPUTIC 60,000.00 1,416,800.00 0 USD SANGAMO BIOSCIENCES 120,000.00 726,000.00 0 USD SEATTLE GENETICS 80,000.00 2,807,200.00 1 USD SEQUENOM 180,000.00 253,800.00 0 USD SEATTLE GENETICS 10,000.00 528,360.00 0 USD TESARO 12,000.00 528,360.00 0 USD TESARO 12,000.00 528,360.00 0 USD TESARO 12,000.00 528,360.00 0 USD TESARO 15,000.00 528,360.00 0 USD THERAVANCE BIO 37,714.00 709,023.20 0 USD ULTRAGENYX PHARMACEUTICAL 15,000.00 949,650.00 0 USD USD UNITED THERAPEUTICS 18,000.00 2,005,740.00 1 USD ULTRAGENYX PHARMACEUTICALS 70,000.00 5,564,300.00 3 SShares (and equity-type securities) 159,588,476.09 95 Securities listed on a stock exchange or other organised markets: Shares (and equity-type securities) 159,588,476.09 95 Securities not listed on a stock exchange: Shares (and equity-type securities) 159,588,476.09 95 Securities not listed on a stock exchange: Shares (and equity-type securities) 14,874,392.48 2 Private Equities 4,874,392.48 2 Total of Portfolio 164,462,868.57 98 Other net assets 166,560.26 0					1.6
USD MERRIMACK PHARMACEUTICALS 100,000.00 837,000.00 0 USD MYRIAD GENETICS 103,400.00 3,870,262.00 2 USD NEXTAR THERAPEUTICS 160,000.00 2,200,000.00 2 USD NEUROCRINE BIOSCIENCES 85,000.00 3,361,750.00 2 DKK NOVO-NORDISK -B. 87,000.00 4,726,632.47 2 USD ONCOMED PHARMACEUTICALS 36,500.00 38,015.00 0 USD PROTHENA CORPORATION 39,600.00 1,629,936.00 0 USD PROTHENA CORPORATION 39,600.00 1,629,936.00 0 USD RADIUS HEALTH 45,000.00 528,660.00 0 USD RADIUS HEALTH 45,000.00 1414,800.00 0 USD REGENERON PHARMACEUTICALS 23,000.00 8,290,120.00 0 USD SEATTLE GENETICS 80,000.00 2,877,200.00 0 USD SEATTLE GENETICS 80,000.00 2,807,200.00 0 USD SECURIOM	USD				0.6
USD MYRIAD GENETICS 103,400.00 3,870,262.00 2 USD NEKTAR THERAPEUTICS 160,000.00 2,200,000.00 1 USD NEUROCRINE BIOSCIENCES 86,000.00 3,817,50.00 2 DKK NOVO-NORDISK -B 87,000.00 4,726,632.47 2 USD ONCOMED PHARMACEUTICALS 36,500.00 369,015.00 0 USD PROTHEINA CORPORATION 39,600.00 1,629,936.00 0 USD PROTHEINA CORPORATION 39,600.00 1,629,936.00 0 USD PROTHEINA CORPORATION 39,600.00 1,629,936.00 0 USD RADIUS HEALTH 45,000.00 528,660.00 0 USD REGILLUS THERAPEUTIC 60,000.00 1,414,800.00 0 USD REGILLUS THERAPEUTIC 60,000.00 415,800.00 4 USD SANGAMO BIOSCIENCES 120,000.00 726,000.00 0 USD SEATTLE GENETICS 80,000.00 2,807,200.00 1 USD SECURED SEATOR BIO 12,000.00 528,360.00 0 USD SEATOR BIO 12,000.00 528,360.00 0 USD TESARO 12,000.00 528,360.00 0 USD TESARO 12,000.00 528,360.00 0 USD TESARO 12,000.00 528,360.00 0 USD THERAVANCE BIO 37,714.00 709,023.20 0 USD ULTRAGENYX PHARMACEUTICAL 15,000.00 949,650.00 0 USD VERTEX PHARMACEUTICALS 70,000.00 5,564,300.00 3 Shares (and equity-type securities) 159,588,476.09 95 Securities listed on a stock exchange or other organised markets: Shares (and equity-type securities) 159,588,476.09 95 Securities not listed on a stock exchange: Shares (and equity-type securities) 159,588,476.09 95 Securities not listed on a stock exchange: Shares (and equity-type securities) 14,874,392.48 2 Private Equities 44,874,392.48 2 Total of Portfolio 164,462,868.57 98 Cother net assets 166,660.26 0 COther net assets 166,660.26 0 COTHER POLYPHOR -D 1,777,096.29 1	USD	MEDIVATION	140,000.00	6,437,200.00	3.8
USD NEKTAR THERAPEUTICS 160,000.00 2,200,000.00 1 USD NEUROCRINE BIOSCIENCES 85,000.00 3,361,750.00 2 DKK NOVO-NORDISK -B- 87,000.00 4,726,632.47 2 USD ONCOMED PHARMACEUTICALS 36,500.00 369,015.00 0 USD PUMA BIOTECHNOLOGY 18,000.00 1,629,936.00 0 USD PUMA BIOTECHNOLOGY 18,000.00 1,414,800.00 0 USD RADIUS HEALTH 45,000.00 1,414,800.00 0 USD REGENERON PHARMACEUTICALS 23,000.00 3,299,120.00 4 USD SEGULENOM 180,000.00 726,000.00 0 USD SEATTLE GENETICS 80,000.00 2,807,200.00 1 USD SEQUENOM 180,000.00 253,800.00 0 USD SEQUENOM 180,000.00 253,800.00 0 USD THERAVANCE BIO 37,714.00 709,023.20 0 USD ULTRAGENYX PHARMACEUTICAL 15,000.00 <td>USD</td> <td>MERRIMACK PHARMACEUTICALS</td> <td>100,000.00</td> <td>837,000.00</td> <td>0.5</td>	USD	MERRIMACK PHARMACEUTICALS	100,000.00	837,000.00	0.5
USD NEUROCRINE BIOSCIENCES 85,000.00 3,361,750.00 2 USD NEUROCRINE BIOSCIENCES 87,000.00 4,726,632,47 2 USD ONCOMED PHARMACEUTICALS 36,500.00 36,901.50 0 USD PROTHENA CORPORATION 39,600.00 1,629,936.00 0 USD PUMA BIOTECHNOLOGY 18,000.00 528,660.00 0 USD RADIUS HEALTH 45,000.00 1,414,800.00 4 USD REGENERON PHARMACEUTICALS 23,000.00 8,290,120.00 4 USD REGULUS THERAPEUTIC 60,000.00 415,800.00 0 USD SANGAMO BIOSCIENCES 120,000.00 726,000.00 0 USD SEAUENOM 180,000.00 2,807,200.00 0 USD SECUENOM 180,000.00 253,800.00 0 USD ULTRAGENYX PHARMACEUTICAL 15,000.00 2,905,740.00 1 USD ULTRAGENYX PHARMACEUTICALS 70,000.00 5,564,300.00 3 USD VERTEX PHARMACEUTICA					2.3
DKK NOVO-NORDISK -B- 87,000.00 4,726,632.47 2 USD ONCOMED PHARMACEUTICALS 36,500.00 369,015.00 0 USD PROTHEINA CORPORATION 39,600.00 1,629,396.00 0 USD PUMA BIOTECHNOLOGY 18,000.00 528,660.00 0 USD RADIUS HEALTH 45,000.00 1,414,800.00 0 USD REGENERON PHARMACEUTICALS 23,000.00 3,290,120.00 4 USD REGULUS THERAPEUTIC 60,000.00 415,800.00 0 USD SANGAMO BIOSCIENCES 120,000.00 726,000.00 0 USD SEQUENOM 180,000.00 2,807,200.00 1 USD SECIENOM 120,000.00 528,360.00 0 USD THERAVANCE BIO 37,714.00 709,023.20 0 USD UITRAGENYX PHARMACEUTICAL 15,000.00 2,965,000 0 USD UITRAGENYX PHARMACEUTICALS 70,000.00 5,564,300.00 3 Shares (and equity-type securities) 159,5					1.3
USD ONCOMED PHARMACEUTICALS 36,500.00 369,015.00 0 USD PWOTHENA CORPORATION 39,600.00 1,629,936.00 0 USD PWIM BIOTECHNOLOGY 18,000.00 528,660.00 0 USD PWIM BIOTECHNOLOGY 18,000.00 1,414,800.00 0 USD RADIUS HEALTH 45,000.00 1,414,800.00 0 USD REGENERON PHARMACEUTICALS 23,000.00 8,290,120.00 4 USD REGENERON PHARMACEUTICALS 23,000.00 726,000.00 0 USD SANGAMO BIOSCIENCES 120,000.00 726,000.00 0 USD SEATTLE GENETICS 80,000.00 22,807,200.00 1 USD SEQUENOM 180,000.00 253,800.00 0 USD SEQUENOM 180,000.00 523,800.00 0 USD TESARO 12,000.00 528,360.00 0 USD THERAVANCE BIO 37,714.00 709,023.20 0 USD ULTRAGENYX PHARMACEUTICAL 15,000.00 949,650.00 0 USD ULTRAGENYX PHARMACEUTICAL 15,000.00 949,650.00 0 USD VERTEX PHARMACEUTICALS 70,000.00 5,564,300.00 3 Shares (and equity-type securities) 159,588,476.09 95 Securities listed on a stock exchange or other organised markets: Shares (and equity-type securities) 159,588,476.09 95 Securities instead on a stock exchange or other organised markets: Shares (and equity-type securities) 159,588,476.09 95 Securities instead on a stock exchange: Shares (and equity-type securities) Private Equities USD ALPHAVAX (pref. shares) -B 453,000.00 62,853.75 0 USD ALPHAVAX (pref. shares) -B 453,000.00 19,425.00 0 USD ALPHAVAX (pref. shares) -B 453,000.00 62,853.75 0 USD ALPHAVAX (pref. shares) -B 453,000.00 62,853.75 0 USD ALPHAVAX (pref. shares) -B 453,000.00 19,425.00 0 USD ALPHAVAX (pref. shares) -B 453,000.00 62,853.75 0 USD ALPHAVAX (pref. shares) -B 453,000.00 62,853.75 0 USD ALPHAVAX (pref. shares) -B 453,000.00 62,853.75 0 USD ALPHAVAX (pref. shares) -B 140,000.00 19,425.00 0 USD ALPHAVAX (pref. shares) -B 140,000.00 19					2.0
USD PROTHENA CORPORATION 39,600.00 1,629,936.00 0 USD PUMA BIOTECHNOLOGY 18,000.00 528,660.00 0 USD RADIUS HEALTH 45,000.00 1,414,800.00 528,660.00 0 USD RADIUS HEALTH 45,000.00 1,414,800.00 0 USD REGENERON PHARMACEUTICALS 23,000.00 8,290,120.00 4 USD REGULUS THERAPEUTIC 60,000.00 726,000.00 0 USD SANGAMO BIOSCIENCES 120,000.00 726,000.00 0 USD SEATTLE GENETICS 80,000.00 2,807,200.00 1 USD SEQUENOM 180,000.00 528,360.00 0 USD SEQUENOM 37,714.00 709,023.20 0 USD USD THERAVANCE BIO 37,714.00 709,023.20 0 USD ULTRAGENYX PHARMACEUTICAL 15,000.00 949,650.00 0 USD ULTRAGENYX PHARMACEUTICAL 15,000.00 2,005,740.00 1 USD UNITED THERAPEUTICS 18,000.00 2,005,740.00 1 USD UNITED THERAPEUTICS 70,000.00 5,564,300.00 3 Shares (and equity-type securities) 159,588,476.09 95 Securities listed on a stock exchange or other organised markets: Shares (and equity-type securities) 159,588,476.09 95 Securities not listed on a stock exchange: Shares (and equity-type securities) USD ALPHAVAX (pref. shares) -B- 453,000.00 62,853.75 0 USD ALPHAVAX (pref. shares) -B- 453,000.00 19,425.00 0 USD ALPHAVAX (pref. shares) -D- 1,765.00 4,792,113.73 2 Private Equities Securities 4,874,392.48 2 Securities not listed on a stock exchange: Shares (and equity-type securities) Private Equities Securities 4,874,392.48 2 Total of Portfolio 164,462,868.57 98 Cash at banks and at brokers 1,777,096.29 1 Other net assets 166,560.26 0					2.8
USD PUMA BIOTECHNOLOGY 18,000.00 528,660.00 0 USD RADIUS HEALTH 45,000.00 1,414,800.00 0 USD REGENERON PHARMACEUTICALS 23,000.00 8,290,120.00 4 USD REGELUS THERAPEUTIC 60,000.00 415,800.00 0 USD SANGAMO BIOSCIENCES 120,000.00 726,000.00 0 USD SANGAMO BIOSCIENCES 120,000.00 2,807,200.00 1 USD SEATTLE GENETICS 80,000.00 253,800.00 0 USD SEATTLE GENETICS 120,000.00 528,360.00 0 USD TESARO 12,000.00 528,360.00 0 USD THERAVANCE BIO 37,714.00 709,023.20 0 USD USD USD USD THERAPEUTICS 18,000.00 949,650.00 0 USD UTHER GENEY PHARMACEUTICAL 15,000.00 949,650.00 0 USD USD USD USD THERAPEUTICS 18,000.00 2,005,740.00 1 USD VERTEX PHARMACEUTICALS 70,000.00 5,564,300.00 3 USD SECURITIES INSTITUTED THE OF THE					0.2
USD RADIUS HEALTH 45,000.00 1,414,800.00 0 USD REGENERON PHARMACEUTICALS 23,000.00 8,290,120.00 4 USD REGELUS THERAPEUTIC 60,000.00 15,800.00 0 USD SANGAMO BIOSCIENCES 120,000.00 726,000.00 0 USD SEATTLE GENETICS 80,000.00 28,807,200.00 1 USD SEQUENOM 180,000.00 253,800.00 0 USD TESARO 12,000.00 528,360.00 0 USD THERAVANCE BIO 37,714.00 709,023.20 0 USD USD UTRAGENYX PHARMACEUTICAL 15,000.00 949,650.00 0 USD UTRED THERAPEUTICS 18,000.00 2,005,740.00 1 USD UNITED THERAPEUTICS 18,000.00 2,005,740.00 1 USD USD UNITED THERAPEUTICALS 70,000.00 5,564,300.00 3 USD Shares (and equity-type securities) 159,588,476.09 95 Securities listed on a stock exchange or other organised markets: Shares (and equity-type securities) 159,588,476.09 95 Securities not listed on a stock exchange: Shares (and equity-type securities) Private Equities USD ALPHAVAX (pref. shares) -B- 453,000.00 62,853.75 0 USD ALPHAVAX (pref. shares) -D- 140,000.00 19,425.00 0 USD ALPHAVAX (pref. shares) -D- 1,765.00 4,792,113.73 2 Private Equities 4,874,392.48 2 Securities not listed on a stock exchange: Shares (and equity-type securities) 150,4874,392.48 2 Total of Portfolio 164,462,868.57 98 Other net assets 166,560.26 0					0.9
USD REGENERON PHARMACEUTICALS 23,000.00 8,290,120.00 4 USD REGULUS THERAPEUTIC 60,000.00 726,000.00 0 USD SANGAMO BIOSCIENCES 120,000.00 726,000.00 0 USD SEATTLE GENETICS 80,000.00 2,807,200.00 1 USD SEQUENOM 180,000.00 528,360.00 0 USD TESARO 12,000.00 528,360.00 0 USD TESARO 12,000.00 528,360.00 0 USD THERAVANCE BIO 37,714.00 709,023.20 0 USD ULTRAGENYX PHARMACEUTICAL 15,000.00 949,650.00 0 USD ULTRAGENYX PHARMACEUTICAL 15,000.00 2,005,740.00 1 USD ULTRED THERAPEUTICS 18,000.00 2,005,740.00 1 USD UNITED THERAPEUTICS 70,000.00 5,564,300.00 3 USD Securities listed on a stock exchange or other organised markets: Shares (and equity-type securities) 159,588,476.09 95 Securities Instead on a stock exchange: Shares (and equity-type securities) Private Equities USD ALPHAVAX (pref. shares) -B- 453,000.00 62,853.75 0 USD ALPHAVAX (pref. shares) -D- 11,765.00 4,792,113.73 2 Private Equities 4,874,392.48 2 Private Equities 4,874,392.48 2 Private Equities 4,874,392.48 2 Total of Portfolio 164,462,868.57 98 Cash at banks and at brokers 1,777,096.29 1 Other net assets 166,560.26 0					0.8
USD REGULUS THERAPEUTIC 60,000.00 415,800.00 0 USD SANGAMO BIOSCIENCES 120,000.00 726,000.00 0 USD SANGAMO BIOSCIENCES 120,000.00 726,000.00 0 USD SANGAMO BIOSCIENCES 80,000.00 2,807,200.00 1 USD SEQUENOM 180,000.00 253,800.00 0 USD THERAVANCE BIO 12,000.00 528,360.00 0 USD THERAVANCE BIO 37,714.00 709,023.20 0 USD ULTRAGENYX PHARMACEUTICAL 15,000.00 949,650.00 0 USD UNITED THERAPEUTICS 18,000.00 2,005,740.00 1 USD VERTEX PHARMACEUTICALS 70,000.00 5,564,300.00 3 USD VERTEX PHARMACEUTICALS 70,000.00 5,564,300.00 3 Shares (and equity-type securities) 159,588,476.09 95 Securities listed on a stock exchange or other organised markets: Shares (and equity-type securities) 159,588,476.09 95 Securities Insted on a stock exchange: Shares (and equity-type securities) Private Equities USD ALPHAVAX (pref. shares) -B- 453,000.00 62,853,75 0 USD ALPHAVAX (pref. shares) -D- 11,765.00 4,792,113.73 2 Private Equities 24,874,392.48 2 Securities not listed on a stock exchange: Shares (and equity-type securities) Private Equities 4,874,392.48 2 Securities not listed on a stock exchange: Shares (and equity-type securities) 164,462,868.57 98 Cash at banks and at brokers 1,777,096.29 1 Chter net assets 166,560.26 0					4.9
USD SANGAMO BIOSCIENCES 120,000.00 726,000.00 0 USD SEATTLE GENETICS 80,000.00 2,807,200.00 1 USD SEQUENOM 180,000.00 253,800.00 0 USD TESARO 12,000.00 528,360.00 0 USD THERAVANCE BIO 12,000.00 528,360.00 0 USD THERAVANCE BIO 37,714.00 709,023.20 0 USD ULTRAGENYX PHARMACEUTICAL 15,000.00 949,650.00 0 USD UNITED THERAPEUTICS 18,000.00 2,005,740.00 1 USD ULTRAGENYX PHARMACEUTICALS 70,000.00 5,564,300.00 3 USD VERTEX PHARMACEUTICALS 70,000.00 5,564,300.00 3 USD VERTEX PHARMACEUTICALS 159,588,476.09 95 Securities listed on a stock exchange or other organised markets: Shares (and equity-type securities) 159,588,476.09 95 Securities not listed on a stock exchange: Shares (and equity-type securities) Private Equities USD ALPHAVAX (pref. shares) -B- 453,000.00 62,853.75 0 USD ALPHAVAX (pref. shares) -D- 140,000.00 19,425.00 0 USD ALPHAVAX (pref. shares) -D- 1,765.00 4,792,113.73 2 Private Equities 4,874,392.48 2 Private Equities Securities (and equity-type securities) 4,874,392.48 2 Total of Portfolio 164,462,868.57 98 Cash at banks and at brokers 1,777,096.29 1 Other net assets 166,560.26 0					0.2
USD SEATTLE GENETICS 80,000.00 2,807,200.00 1 USD SEQUENOM 180,000.00 253,800.00 0 USD TESARO 12,000.00 528,360.00 0 USD TESARO 12,000.00 528,360.00 0 USD THERAVANCE BIO 37,714.00 709,023.20 0 USD ULTRAGENYX PHARMACEUTICAL 15,000.00 949,650.00 0 USD ULTRAGENYX PHARMACEUTICAL 15,000.00 949,650.00 1 USD UNTED THERAPPEUTICS 18,000.00 2,005,740.00 1 USD UNTED THERAPPEUTICS 70,000.00 5,564,300.00 3 Shares (and equity-type securities) 159,588,476.09 95 Securities listed on a stock exchange or other organised markets: Shares (and equity-type securities) 159,588,476.09 95 Securities not listed on a stock exchange: Shares (and equity-type securities) Private Equities USD ALPHAVAX (pref. shares) -B- 453,000.00 62,853.75 0 USD ALPHAVAX (pref. shares) -D- 140,000.00 19,425.00 0 CHF POLYPHOR -D- 1,765.00 4,792,113.73 2 Private Equities 4,874,392.48 2 Securities not listed on a stock exchange: Shares (and equity-type securities) Total of Portfolio 164,462,868.57 98 Cash at banks and at brokers 1,777,096.29 1 Other net assets 166,560.26 0					0.4
USD SEQUENOM 180,000.00 253,800.00 0 USD TESARO 12,000.00 528,360.00 0 USD THERAVANCE BIO 12,000.00 528,360.00 0 USD THERAVANCE BIO 37,714.00 709,023.20 0 USD ULTRAGENYX PHARMACEUTICAL 15,000.00 949,650.00 0 USD UNITED THERAPEUTICS 18,000.00 2,005,740.00 1 USD VERTEX PHARMACEUTICALS 15,000.00 5,564,300.00 1 USD VERTEX PHARMACEUTICALS 15,000.00 949,650.00 0 USD UNITED STAR PHARMACEUTICALS 15,000.00 949,650.00 0 USD UNITED STAR PHARMACEUTICALS 15,000.00 5,564,300.00 1 USD VERTEX PHARMACEUTICALS 15,000.00 5,564,300.00 9 USD VERTEX PHARMACEUTICALS 159,588,476.09 95 USD ALPHAVAY (pref. shares) -B- 453,000.00 62,853,75 0 USD ALPHAVAX (pref. shares) -B- 453,000.00 62,853,75 0 USD ALPHAVAX (pref. shares) -D- 11,765.00 4,792,113.73 2 USD ALPHAVAX (pref. shares) -D- 1,765.00 4,792,113.73 2 USD ALPHAVAX (pref. sha					1.6
USD TESARO 12,000.00 528,360.00 0 USD THERAVANCE BIO 37,714.00 709,023.20 0 USD ULTRAGENYX PHARMACEUTICAL 15,000.00 949,660.00 0 USD ULTRAGENYX PHARMACEUTICAL 15,000.00 949,660.00 1 USD ULTRAGENYX PHARMACEUTICAL 15,000.00 2,005,740.00 1 USD VERTEX PHARMACEUTICALS 70,000.00 5,564,300.00 3 Shares (and equity-type securities) 159,588,476.09 95 Securities listed on a stock exchange or other organised markets: Shares (and equity-type securities) 159,588,476.09 95 Securities not listed on a stock exchange: Shares (and equity-type securities) Private Equities USD ALPHAVAX (pref. shares) -B- 453,000.00 62,853.75 0 USD ALPHAVAX (pref. shares) -D- 140,000.00 19,425.00 0 CHF POLYPHOR -D- 1,765.00 4,792,113.73 2 Private Equities 4,874,392.48 2 Securities not listed on a stock exchange: Shares (and equity-type securities) 4,874,392.48 2 Total of Portfolio 164,462,868.57 98 Cash at banks and at brokers 1,777,096.29 1 Other net assets 166,560.26 0					0.1
USD THERAVANCE BIO 37,714.00 709,023.20 0 USD ULTRAGENTX PHARMACEUTICAL 15,000.00 948,650.00 0 USD ULTRAGENTX PHARMACEUTICAL 15,000.00 948,650.00 0 USD UNTED THERAPEUTICS 18,000.00 2,005,740.00 1 USD UNTED THERAPEUTICS 70,000.00 5,564,300.00 3 Shares (and equity-type securities) 159,588,476.09 95 Securities listed on a stock exchange or other organised markets: Shares (and equity-type securities) 159,588,476.09 95 Securities not listed on a stock exchange: Shares (and equity-type securities) Private Equities USD ALPHAVAX (pref. shares) -B- 453,000.00 62,853.75 0 USD ALPHAVAX (pref. shares) -D- 140,000.00 19,425.00 0 CHF POLYPHOR -D- 1,765.00 4,792,113.73 2 Private Equities 4,874,392.48 2 Securities not listed on a stock exchange: Shares (and equity-type securities) Total of Portfolio 164,462,868.57 98 Cash at banks and at brokers 1,777,096.29 1 Other net assets 166,560.26 0					0.3
USD UNITED THERAPEUTICS 18,000.00 2,005,740.00 1 USD VERTEX PHARMACEUTICALS 70,000.00 5,564,300.00 3 Shares (and equity-type securities) 159,588,476.09 95 Securities listed on a stock exchange or other organised markets: 159,588,476.09 95 Securities not listed on a stock exchange: Shares (and equity-type securities) Private Equities USD ALPHAVAX (pref. shares) -B- 453,000.00 62,863.75 0 USD ALPHAVAX (pref. shares) -D- 140,000.00 19,425.00 0 CHF POLYPHOR -D- 1,765.00 4,792,113.73 2 Private Equities 4,874,392.48 2 Securities not listed on a stock exchange: Shares (and equity-type securities) 4,874,392.48 2 Total of Portfolio 164,462,868.57 98 Cash at banks and at brokers 1,7777,096.29 1 Other net assets 166,560.26 0		THERAVANCE BIO		709,023.20	0.4
Shares (and equity-type securities) 159,588,476.09 95					0.5
Shares (and equity-type securities) 159,588,476.09 95					1.2
Securities listed on a stock exchange or other organised markets: 159,588,476.09 95	USD	VERTEX PHARMACEUTICALS	70,000.00	5,564,300.00	3.3
Securities Isted on a stock exchange or other organised markets:	Share	es (and equity-type securities)		159 588 476 09	95.9
Securities not listed on a stock exchange: Shares (and equity-type securities) Private Equities USD ALPHAVAX (pref. shares) -B- 453,000.00 62,853.75 0 USD ALPHAVAX (pref. shares) -D- 140,000.00 19,425.00 0 CHF POLYPHOR -D- 1,765.00 4,792,113.73 2 Private Equities 4,874,392.48 2 Securities not listed on a stock exchange: Shares (and equity-type securities) 4,874,392.48 2 Total of Portfolio 164,462,868.57 98 Cash at banks and at brokers 1,777,096.29 1 Other net assets 166,560.26 0	Secur	ities listed on a stock exchange or other organ	nised markets:		
Private Equities USD ALPHAVAX (pref. shares) -B- 453,000.00 62,853.75 0 USD ALPHAVAX (pref. shares) -D- 140,000.00 19,425.00 0 CHF POLYPHOR -D- 1,765.00 4,792,113.73 2 Private Equities 4,874,392.48 2 Securities not listed on a stock exchange: Shares (and equity-type securities) 4,874,392.48 2 Total of Portfolio 164,462,868.57 98 Cash at banks and at brokers 1,777,096.29 1 Other net assets 166,560.26 0	Share	es (and equity-type securities)		159,588,476.09	95.9
USD ALPHAVAX (pref. shares) -B- 453,000.00 62,853.75 0 0 0 0 0 0 0 0 0			ind equity-type secu	rities)	
USD ALPHAVAX (pref. shares) -D- 140,000.00 19,425.00 0 CHF POLYPHOR -D- 1,765.00 4,792,113.73 2 Private Equities Securities not listed on a stock exchange: Shares (and equity-type securities) 4,874,392.48 2 Total of Portfolio 164,462,868.57 98 Cash at banks and at brokers 1,777,096.29 1 Other net assets 166,560.26 0			450.000.55	00.050.55	
CHF POLYPHOR -D- 1,765.00 4,792,113.73 2 Private Equities 4,874,392.48 2 Securities not listed on a stock exchange: Shares (and equity-type securities) 4,874,392.48 2 Total of Portfolio 164,462,868.57 98 Cash at banks and at brokers 1,777,096.29 1 Other net assets 166,560.26 0		•			0.0
Private Equities					0.0 2.8
Securities not listed on a stock exchange: Shares (and equity-type securities) 4,874,392.48 2 Total of Portfolio 164,462,968.57 98 Cash at banks and at brokers 1,777,096.29 1 Other net assets 166,560.26 0			1,703.00		
Total of Portfolio 164,462,868.57 98 Cash at banks and at brokers 1,777,096.29 1 Other net assets 166,560.26 0	Secur	ities not listed on a stock exchange: Shares (a	ind equity-type		2.9
Cash at banks and at brokers 1,777,096.29 1 Other net assets 166,560.26 0					
Other net assets 166,560.26 0					98.8
100,000.20	Cash a	at banks and at brokers		1,777,096.29	1.0
Total net assets 166,406,525.12 100	Other	net assets		166,560.26	0.1
100,100,020.12	Total	net assets		166,406,525,12	100.0
	Juli			.00, .00,020.12	.00.0

Technical Data

		Valoren	ISIN	Management Fee	Total Expense Ratio
B -Capitalisation	USD	2388494	LU0240067867	1.92%	2.26%
UB -Capitalisation	USD	26410560	LU1144414064	1.15%	1.53%
BH -Capitalisation	CHF	3805022	LU0348405399	1.92%	2.28%
UBH -Capitalisation	CHF	26378294	LU1144414148	1.15%	1.52%
BH -Capitalisation	EUR	2388503	LU0240068089	1.92%	2.26%
IBH -Capitalisation	EUR	11085584	LU0491231675	1.20%	1.55%
UBH -Capitalisation	EUR	26378296	LU1144414221	1.15%	1.54%

As at 16.12.2015 Credit Suisse (Lux) Energy Equity Fund has been renamed in Credit Suisse (Lux) Global Energy Winners Equity Fund.

Fund Performance

		YTD	Since Inception	2015	2014	2013
B -Capitalisation	USD	2.67%	/	-27.31%	-20.46%	12.16%
UB -Capitalisation	USD	2.87%	-24.62%	/	/	/
BH -Capitalisation	CHF	2.33%	-37.27%	-28.51%	-20.77%	/
UBH -Capitalisation	CHF	2.61%	-25.96%	/	/	/
BH -Capitalisation	EUR	2.51%	/	-27.99%	-20.65%	11.39%
IBH -Capitalisation	EUR	2.73%	-43.19%	-27.50%	/	/
UBH -Capitalisation	EUR	2.76%	-25.23%	/	/	/

Notes

Forward foreign exchange contracts

Purchases		Sales		Maturity	Valuation
Counterparty					(in USD)
EUR	5,716,995.44	USD	-6,374,427.04	15.06.2016	156,079.70
Credit Suisse Zürich					
CHF	818,945.05	USD	-834,408.31	15.06.2016	23,755.20
Credit Suisse Zürich					
EUR	628.44	USD	-698.93	15.06.2016	18.94
Credit Suisse Zürich					
CHF	17,027.75	USD	-17,700.84	15.06.2016	142.35
Credit Suisse Zürich					
USD	23,471.67	CHF	-22,653.00	15.06.2016	-265.24
Credit Suisse Zürich					
EUR	902.59	USD	-1,008.64	15.06.2016	22.39
Credit Suisse Zürich					
USD	25,638.48	CHF	-24,948.10	15.06.2016	-502.62
Credit Suisse Zürich					
EUR	521.23	USD	-594.84	15.06.2016	0.56
Credit Suisse Zürich					
Net unrealised gain	on forward foreign e	xchange contracts			179,251.28

Statement of Net Assets in USD and Fund Evolution

	31.03.2016
Assets	
Investments in securities at market value	73,905,797.19
Cash at banks and at brokers	350,318.05
Subscriptions receivable	1,949.43
Income receivable	145,836.87
Net unrealised gain on forward foreign exchange contracts	179,251.28
	74,583,152.82
Liabilities	
Redemptions payable	43,448.61
Provisions for accrued expenses	138,042.94
Other liabilities	8.52
	181,500.07
Net assets	74,401,652.75

Fund Evolution		31.03.2016	30.09.2015	30.09.2014
Total net assets	USD	74,401,652.75	81,168,662.80	189,364,186.85
Net asset value per share				
B -Capitalisation	USD	69.29	68.06	120.02
UB -Capitalisation	USD	75.38	73.76	/
BH -Capitalisation	CHF	62.73	62.10	110.81
UBH -Capitalisation	CHF	74.04	72.94	/
BH -Capitalisation	EUR	57.09	56.26	99.95
IBH -Capitalisation	EUR	568.12	557.72	983.88
UBH -Capitalisation	EUR	74.77	73.38	/

Number of shares outstanding		at the end of the period	at the beginning of the period	Number of shares issued	Number of shares redeemed
B -Capitalisation	USD	914,248.571	1,064,606.051	26,138.898	176,496.378
UB -Capitalisation	USD	49,198.407	11,440.000	39,208.407	1,450.000
BH -Capitalisation	CHF	11,651.546	13,018.384	30,725.686	32,092.524
UBH -Capitalisation	CHF	903.851	398.851	805.000	300.000
BH -Capitalisation	EUR	98,968.313	110,933.472	2,314.864	14,280.023
IBH -Capitalisation	EUR	47.906	57.056	3.654	12.804
UBH -Capitalisation	EUR	510.920	98.920	412.000	0.000

Page 33

Statement of Operations / Changes in Net Assets in USD

For the period from 01.10.2015 to 31.03.2016

Net assets at the beginning of the period	81,168,662.80
Income	
Dividends (net)	848,214.93
Securities lending income	14,465.88
	862,680.81
Expenses	
Management fee	741,845.67
Custodian and safe custody fees	17,588.96
Administration expenses	39,082.03
Printing and publication expenses	13,485.43
Interest and bank charges	39.55
Audit, control, legal, representative bank and other expenses	64,256.19
"Taxe d'abonnement"	19,342.62
	895,640.45
Net income (loss)	-32,959.64
Realised gain (loss)	
Net realised gain (loss) on sales of investments	-13,799,048.99
Net realised gain (loss) on forward foreign exchange contracts	-402,800.65
Net realised gain (loss) on foreign exchange	70,150.05
	-14,131,699.59
Net realised gain (loss)	-14,164,659.23
Change in net unrealised appreciation (depreciation)	
Change in net unrealised appreciation (depreciation) on investments	15,058,607.94
Change in net unrealised appreciation (depreciation) on forward foreign exchange contracts	291,486.06
	15,350,094.00
Net increase (decrease) in net assets as a result of operations	1,185,434.77
Subscriptions / Redemptions	
Subscriptions Subscriptions	7,199,541.19
Redemptions	-15,151,986.01
reactifitions	-13,151,960.01 - 7,952,444.8 2
Not asset at the and of the model	
Net assets at the end of the period	74,401,652.75

Breakdown by Country and Economic Sector of the Investments in Securities Statement of Investments in Securities and Other Net Assets

Breakdown by Country

USA	56.84
United Kingdom	9.13
France	8.54
Canada	6.98
Germany	4.58
Hong Kong	3.12
People's Republic of China	2.46
Spain	2.06
Netherlands	1.51
Brazil	1.33
Thailand	1.31
Australia	0.83
Virgin Islands (UK)	0.64
Total	99.33

Breakdown by Economic Sector

Petroleum	66.75
Energy and water supply	11.35
Chemicals	8.77
Electrical appliances and components	5.27
Financial, investment and other div. companies	2.44
Environmental services and recycling	2.06
Vehicles	2.05
Agriculture and fishery	0.64
Total	99.33

Statement of Investments in Securities and Other Net Assets

	Description	Quantity / Nominal	Valuation (in USD)	% of net assets
Secu	rities listed on a stock exchange or other organ	ised markets: Share	s (and equity-type	securities)
Share	es (and equity-type securities)			
USD	A O SMITH	20,000.00	1,526,200.00	2.05
USD	ABENGOA YIELD	100,000.00	1,778,000.00	2.39
USD	ACUITY BRANDS	18,000.00	3,926,520.00	5.27
USD	ANADARKO PETROLEUM	24,000.00	1,117,680.00	1.50
USD	BAKER HUGHES	51,905.00	2,274,996.15	3.06
USD	CABOT OIL & GAS	89,000.00	2,021,190.00	2.72
USD	CANADIAN NATURAL RESOURCES	70,000.00	1,890,000.00	2.54
USD	CARRIZO OIL & GAS	28,000.00	865,760.00	1.16
HKD	CHINA PETROLEUM & CHEMICAL -H-	2,792,000.00	1,832,170.58	2.46
USD	CNOOC ADR	19,800.00	2,317,788.00	3.12
USD	CONCHO RESOURCES	21,000.00	2,121,840.00	2.85
USD	CORE LABORATORIES	10,000.00	1,124,100.00	1.51
USD	DIAMONDBACK ENERGY	40,000.00	3,087,200.00	4.15
EUR	EDP RENOVAVEIS	200,000.00	1,529,276.10	2.06
USD	EQT CORP	30,000.00	2,017,800.00	2.71
USD	HALLIBURTON	24,000.00	857,280.00	1.15
USD	HESS	15,000.00	789,750.00	1.06
USD	KINDER MORGAN	80,000.00	1,428,800.00	1.92
CAD	MEG ENERGY	70,000.00	354,478.56	0.48
USD	NEWFIELD EXPLORATION	45,000.00	1,496,250.00	2.01
USD	OCEANEERING INTERNATIONAL	21,000.00	698,040.00	0.94
USD	PATTERN ENERGY GROUP -A-	115,000.00	2,193,050.00	2.95
USD	PETROLEO BRASILIERO ADR	170,000.00	992,800.00	1.33
USD	PHILLIPS 66	36,000.00	3,117,240.00	4.19
USD	PIONEER NATURAL RESOURCES	15,000.00	2,111,100.00	2.84
THB	PTT GLOBAL CHEMICAL PUBLIC (for. reg. shares)	565,300.00	972,162.20	1.31
USD	ROYAL DUTCH SHELL ADR -B-	50,000.00	2,459,500.00	3.31
AUD	SANTOS	200,000.00	620,006.28	0.83
GBP	SOCO INTERNATIONAL	500,000.00	1,139,046.78	1.53
USD	SUNCOR ENERGY	80,000.00	2,224,800.00	2.99
EUR	TECHNIP	20,000.00	1,110,149.61	1.49
USD	TERRAFORM POWER -A-	200,000.00	1,730,000.00	2.33
USD	TESORO	60,000.00	5,160,600.00	6.93
EUR	TOTAL	115,000.00	5,249,792.90	7.05
GBP	TULLOW OIL	500,000.00	1,415,005.11	1.90
USD	US SILICA HOLDINGS	80,000.00	1,817,600.00	2.44
USD	VALERO ENERGY	19,000.00	1,218,660.00	1.64
EUR	WACKER CHEMIE	38,634.00	3,404,922.48	4.58
CAD	WHITECAP RESOURCES	120,000.00	718,080.02	0.97
USD	WILLIAMS COMPANIES	45,000.00	723,150.00	0.97
Share	es (and equity-type securities) rities listed on a stock exchange or other organ	ised markets:	73,432,784.77	98.69
	es (and equity-type securities)		73,432,784.77	98.69
Secu	rities not listed on a stock exchange: Shares (a	nd equity-type secur	ities)	
	es (and equity-type securities)			
USD	UNION AGRICULTURE GROUP	49,817.00	473,012.42	0.64
Share	es (and equity-type securities) rities not listed on a stock exchange: Shares (a	nd equity-type	473,012.42	0.64
secu		nu equity-type	473,012.42	0.64
Total	of Portfolio		73,905,797.19	99.33
Cash	at banks and at brokers		350,318.05	0.47
Other	net assets		145,537.51	0.20
Total	net assets		74,401,652.75	100.00

Technical Data

		Valoren	ISIN	Management Fee	Total Expense Ratio
B -Capitalisation	USD	3786494	LU0348402883	1.92%	2.32%
EB -Capitalisation	USD	23894605	LU1043177150	0.90%	1.24%
IB -Capitalisation	USD	3786497	LU0348402966	1.20%	1.60%
UB -Capitalisation	USD	26124895	LU1139005398	1.15%	1.57%
UBH -Capitalisation	CHF	26383536	LU1144422752	1.15%	1.54%
IBH -Capitalisation	EUR	25675280	LU1120907206	1.20%	1.61%
UBH -Capitalisation	EUR	26383540	LU1144422836	1.15%	1.55%
UBH -Capitalisation	GBP	26124898	LU1139012410	1.15%	1.55%

Fund Performance

	YTD	Since Inception	2015	2014	2013
USD	5.34%	/	-11.93%	4.61%	4.92%
USD	5.61%	-10.84%	/	/	/
USD	5.53%	/	-11.28%	5.37%	5.72%
USD	5.54%	-7.85%	/	/	/
CHF	5.03%	-9.40%	/	/	/
EUR	5.23%	-4.21%	-11.43%	/	/
EUR	5.25%	-8.35%	/	/	/
GBP	5.20%	-8.17%	/	/	/
	USD USD USD CHF EUR EUR	USD 5.34% USD 5.61% USD 5.53% USD 5.54% CHF 5.03% EUR 5.23%	USD 5.34% / USD 5.61% -10.84% USD 5.53% / USD 5.54% -7.85% CHF 5.03% -9.40% EUR 5.23% -4.21% EUR 5.25% -8.35%	USD 5.34% / -11.93% USD 5.61% -10.84% / USD 5.53% / -11.28% USD 5.54% -7.85% / CHF 5.03% -9.40% / EUR 5.23% -4.21% -11.43% EUR 5.25% -8.35% /	USD 5.34% / -11.93% 4.61% USD 5.61% -10.84% / / USD 5.53% / -11.28% 5.37% USD 5.54% -7.85% / / CHF 5.03% -9.40% / / EUR 5.23% -4.21% -11.43% / EUR 5.25% -8.35% / /

Forward foreign exchange contracts

Purchases		Sales		Maturity	Valuation
Counterparty					(in USD)
CHF	8,570.00	USD	-8,721.84	15.06.2016	258.57
Morgan Stanley Cap	ital Services New York				
EUR	98,398.00	USD	-109,337.55	15.06.2016	3,062.19
Morgan Stanley Cap	ital Services New York				
GBP	8,646.00	USD	-12,365.52	15.06.2016	67.45
Morgan Stanley Cap	ital Services New York				
GBP	380.00	USD	-551.21	15.06.2016	-4.77
Morgan Stanley Cap	ital Services New York				
CHF	313.00	USD	-324.95	15.06.2016	3.04
Morgan Stanley Cap	ital Services New York				
EUR	4,303.00	USD	-4,869.47	15.06.2016	45.83
Morgan Stanley Cap	ital Services New York				
USD	211.21	CHF	-204.00	15.06.2016	-2.55
Morgan Stanley Cap	ital Services New York				
USD	294.66	GBP	-205.00	15.06.2016	-0.13
Morgan Stanley Cap	ital Services New York				
USD	2,639.85	EUR	-2,338.00	15.06.2016	-30.77
Morgan Stanley Cap	nital Services New York				
CHF	243.00	USD	-254.49	15.06.2016	0.15
Morgan Stanley Cap	nital Services New York				
GBP	249.00	USD	-358.64	15.06.2016	-0.58
Morgan Stanley Cap	ital Services New York				
EUR	2,818.00	USD	-3,218.68	15.06.2016	0.31
Morgan Stanley Cap	ital Services New York				
Net unrealised gai	n on forward foreign exc	change contracts			3,398.74

Statement of Net Assets in USD and Fund Evolution

	31.03.2016
Assets	
Investments in securities at market value	104,160,709.80
Cash at banks and at brokers	2,568,668.86
Subscriptions receivable	23,933.25
Income receivable	414,603.50
Net unrealised gain on forward foreign exchange contracts	3,398.74
	107,171,314.15
Liabilities	
Due to banks and to brokers	1,090,487.01
Redemptions payable	78,843.69
Provisions for accrued expenses	187,820.72
Other liabilities	5,732.42
	1,362,883.84
Net assets	105,808,430.31

Fund Evolution		31.03.2016	30.09.2015	30.09.2014
Total net assets	USD	105,808,430.31	107,317,913.07	48,438,112.91
Net asset value per share				
B -Capitalisation	USD	124.32	121.07	135.33
EB -Capitalisation	USD	891.60	863.70	/
IB -Capitalisation	USD	116.48	113.03	125.43
UB -Capitalisation	USD	92.15	89.40	/
UBH -Capitalisation	CHF	90.60	88.67	/
IBH -Capitalisation	EUR	957.93	933.00	/
UBH -Capitalisation	EUR	91.65	89.24	/
UBH -Capitalisation	GBP	91.83	89.26	/

Number of shares outstanding		at the end of the period	at the beginning of the period	Number of shares issued	Number of shares redeemed
B -Capitalisation	USD	170,748.009	203,830.337	12,243.982	45,326.310
EB -Capitalisation	USD	87,179.337	86,070.950	21,597.105	20,488.718
IB -Capitalisation	USD	55,640.661	74,608.950	8,334.047	27,302.336
UB -Capitalisation	USD	2,488.798	1,388.798	1,100.000	0.000
UBH -Capitalisation	CHF	98.851	98.851	125.000	125.000
IBH -Capitalisation	EUR	98.646	113.531	0.000	14.885
UBH -Capitalisation	EUR	98.919	98.919	0.000	0.000
UBH -Capitalisation	GBP	99.169	99.169	0.000	0.000

Statement of Operations / Changes in Net Assets in USD

For the period from 01.10.2015 to 31.03.2016

Net assets at the beginning of the period	107,317,913.07
Income	
Dividends (net)	863,933.49
Bank interest	1,070.80
	865,004.29
Expenses	
Management fee	626,018.29
Custodian and safe custody fees	24,066.02
Administration expenses	55,457.74
Printing and publication expenses	16,088.60
Interest and bank charges	20,266.21
Audit, control, legal, representative bank and other expenses	110,379.02
"Taxe d'abonnement"	12,125.41
	864,401.29
Net income (loss)	603.00
Realised gain (loss)	
Net realised gain (loss) on sales of investments	-10,570,387.79
Net realised gain (loss) on forward foreign exchange contracts	-154.47
Net realised gain (loss) on foreign exchange	-154,018.95
	-10,724,561.21
Net realised gain (loss)	-10,723,958.21
Change in net unrealised appreciation (depreciation)	
Change in net unrealised appreciation (depreciation) Change in net unrealised appreciation (depreciation) on investments	12,241,588.43
Change in net unrealised appreciation (depreciation) on forward foreign exchange contracts	5,318.67
Online a measured appropriation (depreciation) on torward to ognitive and extraction	12,246,907.10
Net increase (decrease) in net accets as a result of anarotions	1 500 040 00
Net increase (decrease) in net assets as a result of operations	1,522,948.89
Subscriptions / Redemptions	
Subscriptions	21,715,915.72
Redemptions	-24,748,347.37
	-3,032,431.65
Net assets at the end of the period	105,808,430.31

Breakdown by Country South Korea Brazil 11.45 11.29 Taiwan South Africa 11.22 Cayman Islands 7.73 6.59 India Turkey 6.41 People's Republic of China 6.14 Indonesia 4.25 3.06 Bermuda Thailand 2.66 Hong Kong 2.41 Luxembourg 1.16 Malaysia 1.09 Singapore 1.00 USA 0.97 Panama 0.78 Greece 0.71 Russia 0.71 Philippines 0.70 Mexico 0.62 Hungary 0.62 Qatar 0.55 Total 98.44

Total	98.44
Lodging and catering industry, leisure facilities	0.62

Breakdown by Economic Sector

Real estate	9.27
Food and soft drinks	8.63
Energy and water supply	7.84
Financial, investment and other div. companies	7.58
Electronics and semiconductors	7.27
Pharmaceuticals, cosmetics and medical products	6.13
Telecommunication	5.99
Banks and other credit institutions	5.94
Insurance companies	5.05
Petroleum	4.80
Textiles, garments and leather goods	3.31
Traffic and transportation	3.03
Retailing, department stores	3.02
Computer hardware and networking	2.53
Miscellaneous consumer goods	2.46
Vehicles	1.81
Internet, software and IT services	1.78
Building materials and building industry	1.59
Mechanical engineering and industrial equipment	1.29
Miscellaneous services	1.16
Rubber and tires	1.09
Non-ferrous metals	1.07
Tobacco and alcoholic beverages	1.05
Chemicals	1.03
Electrical appliances and components	0.91
Mortgage and funding institutions (MBA, ABS)	0.89
Healthcare and social services	0.66
Mining, coal and steel industry	0.64

Statement of Investments in Securities and Other Net Assets

	Description	Quantity / Nominal	Valuation (in USD)	% of ne assets
Secur	ities listed on a stock exchange or other organis	ed markets: Share	s (and equity-type	securities
	es (and equity-type securities)			
MXN	ALSEA SAB DE CV	173,000.00	654,539.44	0.63
KRW	AMOREPACIFIC (new)	1,500.00	506,951.70	0.48
HKD	ANTA SPORTS PRODUCTS	445,000.00	979,897.36	0.93
NR	AUROBINDO PHARMA	75,000.00	843,633.20	0.80
JSD	BANCO LATINOAMERICANO DE EXPORTACIONES -E-	34,000.00	823,480.00	0.78
ΓWD	CATCHER TECHNOLOGY	117,000.00	959,732.26	0.9
JSD	CHINA BIOLOGIC PRODUCTS	9,000.00	1,030,320.00	0.9
HKD	CHINA COMMUNICATIONS SERVICES -H-	2,546,000.00	1,161,968.54	1.10
HKD	CHINA HONGQIAO GROUP	1,625,000.00	1,129,210.32	1.0
HKD	CHINA LESSO GROUP HOLDINGS	2,542,000.00	1,363,331.86	1.29
HKD	CHINA NATIONAL BUILDING MATERIAL -H-	880,000.00	408,430.23	0.39
HKD	CHINA POWER INTERNATIONAL DEVELOPMENT	1,636,000.00	847,894.97	0.80
WD	CHLITINA HOLDING	67,000.00	576,653.42	0.5
HKD	CHONGQING RURAL COMMERCIAL BANK -H-	4,524,000.00	2,391,328.07	2.26
3RL	CIA ENERGETICA DE MINAS GERAIS (pref.	1.00	2.28	0.00
	shares)	4 555 000 00		
WD	COMPAL ELECTRONICS	1,779,000.00	1,116,574.28	1.06
HKD	COSMO LADY (CHINA) HOLDINGS	605,000.00	489,052.66	0.46
BRL	CYRELA BRAZIL REALTY	488,000.00	1,436,172.73	1.36
(RW	DGB FINANCIAL GROUP	254,000.00 2,697,000.00	1,976,740.01	1.8
WD WD	E INK HOLDINGS ECLAT TEXTILE	69,563.00	1,558,670.06	1.4'
RY	EMLAK KONUT GAYRIMENKUL YATIRIM		915,360.19 2,798,939.22	0.8 2.6
RY BRL	ENERGIAS DO BRASIL	2,746,000.00 759,000.00	2,798,939.22	2.6
KD	FAR EAST HORIZON	2,211,000.00	1,704,600.59	1.6
WD	FORMOSA TAFFETA	1,133,000.00	1,107,161.21	1.0
WD	GRAPE KING	163,000.00	934,424.63	0.8
'AR	GROWTHPOINT PROPERTIES (units)	1,173,000.00	1,959,519.47	1.8
łKD	HAIER ELECTRONICS GROUP	888,000.00	1,547,826.81	1.4
RW	HANSSEM	10,400.00	2,032,528.75	1.9
NR	HERO MOTOCORP	43,000.00	1,912,719.99	1.8
lKD	HUANENG POWER INTERNATIONAL	1,027,000.00	918,888.09	0.8
JSD	INDIABULLS HOUSING (REGS-)	96,000.00	937,152.00	0.8
NR	INTERGLOBE AVIATION	52,000.00	685,507.19	0.6
JSD	JA SOLAR HOLDINGS ADR	101,000.00	869,610.00	0.8
łKD	KERRY PROPERTIES	616,000.00	1,691,581.88	1.6
WD	KING'S TOWN BANK	1,808,000.00	1,244,321.08	1.1
RW	KT CORPORATION	59,511.00	1,550,741.26	1.4
RW	KT& G CORP	11,000.00	1,058,062.20	1.0
RW	LG HOUSEHOLD & HEALTHCARE	2,900.00	2,396,379.72	2.2
RW	LG UPLUS	215,000.00	2,077,430.81	1.9
ZAR	LIBERTY HOLDINGS	292,000.00	2,870,168.86	2.7
PHP	MANILA WATER	1,266,000.00	742,360.45	0.70
BRL	MARFRIG ALIMENTOS	943,000.00	1,726,867.17	1.6
RW	MEDY-TOX	3,000.00	1,158,184.62	1.0
JSD	MOSCOW EXCHANGE MICEX	479,000.00	752,601.45	0.7
UR	MOTOR OIL HELLAS	70,000.00	754,610.01	0.7
NR	MRF (demat. shares)	2,000.00	1,156,608.40	1.0
BRL	MRV ENGENHARIA	379,000.00	1,266,174.19	1.2
(RW /IYR	MUHAK CO	1,634.00	51,509.00	0.0
RW.	MY E.G.SERICES BERHAD OTTOGI CORPORATION	2,108,000.00	1,156,253.85	1.0
RW.	PARTRON	600.00 102.000.00	475,865.66 1,083,683.05	1.0
WD	PEGATRON	915,000.00	2,135,115.30	2.0
WD	PHISON ELECTRONICS	240,000.00	1,953,767.30	1.8
WD BRL	PORTO SEGURO	241,000.00	1,852,365.53	1.7
DR.	PT INDO TAMBANGRAYA MEGAH	1,353,000.00	675,989.79	0.6
DR DR	PT INDOFOOD SUKSES MAKMUR	5,668,000.00	3,088,333.18	2.9
DR.	PT LINK NET TBK	2,371,000.00	734,008.64	0.6
HB	PTT GLOBAL CHEMICAL PUBLIC (nvdr)	615,000.00	1,057,632.68	1.0
AR	OATAR NAVIGATION	23,000.00	577,939.48	0.5
lUF	RICHTER GEDEON	33,000.00	658,191.86	0.6
JR	RURAL ELECTRIFICATI	571,000.00	1,433,050.70	1.3
GD	SEMBCORP INDUSTRIES	471,000.00	1,056,282.76	1.0
IKD	SINOPEC ENGINEERING (GROUP) -H-	1,988,000.00	1,609,565.79	1.5
RW		30,000.00	1,088,667.31	1.0
RL	SUL AMERICA (units)	139,000.00	629,495.14	0.5
AR	SUPER GROUP	653,022.00	1,937,577.00	1.8
SD	TAL EDUCATION GROUP -A- ADR	14,000.00	695,520.00	0.6
RY	TAT GIDA SANAYI	389,000.00	819,247.89	0.7
RY	TEKFEN HOLDING	780,000.00	1,506,969.77	1.4
SD	TERNIUM ADR	68,000.00	1,222,640.00	1.1
НВ	THAI VEGETABLE OIL PUBLIC NON VOTING	2,645,000.00	1,759,324.32	1.6
RL	DEPOSITARY RECEIPT TRANSMISSORA ALIANCA DE ENERGIA	441,000.00	2,511,090.10	2.3
AR	ELETRICA (units) TRUWORTH INTERNATIONAL	479,000.00	3,198,761.49	3.0
RY	TUPRAS	59,000.00	1,662,685.01	1.5
IKD	WH GROUP	1,749,000.00	1,267,239.88	1.2
AR	WILSON BAYLY HOLMES - OVCON	237,000.00	1,917,528.04	1.8
		,000.00	1,819,866.99	0

Description	Quantity / Nominal	Valuation (in USD)	% of net assets
HKD XINIY GLASS HOLDINGS	1,202,000.00	801,175.61	0.76
Shares (and equity-type securities) Securities listed on a stock exchange or other org	anised markets:	104,160,709.80	98.44
Shares (and equity-type securities)		104,160,709.80	98.44
Total of Portfolio		104,160,709.80	98.44
Cash at banks and at brokers		2,568,668.86	2.43
Due to banks and to brokers		-1,090,487.01	-1.03
Other net assets		169,538.66	0.16
Total net assets		105,808,430.31	100.00

Page 41

Technical Data and Notes

Technical Data

		Valoren	ISIN	Management Fee	Total Expense Ratio
B -Capitalisation	USD	2459821	LU0246496953	2.00%	2.27%
EB -Capitalisation	USD	23791292	LU1038193931	0.90%	1.25%
IB -Capitalisation	USD	2459825	LU0246497258	1.20%	1.55%
UB -Capitalisation	USD	26379366	LU1144414494	1.15%	1.53%
BH -Capitalisation	EUR	2459827	LU0246498066	2.00%	2.28%
IBH -Capitalisation	EUR	3805028	LU0348405472	1.20%	1.57%
UBH -Capitalisation	EUR	26379367	LU1144414577	1.15%	1.53%

Fund Performance

		YTD	Since Inception	2015	2014	2013
B -Capitalisation	USD	6.12%	/	-6.69%	9.15%	10.64%
EB -Capitalisation	USD	6.40%	-4.87%	-5.69%	/	/
IB -Capitalisation	USD	6.31%	/	-6.01%	9.93%	11.48%
UB -Capitalisation	USD	6.32%	-0.89%	/	/	/
BH -Capitalisation	EUR	5.80%	/	-7.31%	8.79%	9.95%
IBH -Capitalisation	EUR	6.00%	-1.45%	-6.48%	/	/
UBH -Capitalisation	EUR	6.02%	-1.71%	/	/	/

Notes

Forward foreign exchange contracts

Purchases		Sales		Maturity	Valuation
Counterparty					(in USD)
EUR	14,396,575.80	USD	-16,052,124.44	15.06.2016	393,040.91
Credit Suisse 2	Zürich				
Net unrealise	d gain on forward foreign e	xchange contracts	3		393,040.91

Statement of Net Assets in USD and Fund Evolution

	31.03.2016
Assets	
Investments in securities at market value	75,729,110.76
Cash at banks and at brokers	1,452,877.18
Income receivable	84,945.07
Net unrealised gain on forward foreign exchange contracts	393,040.91
	77,659,973.92
Liabilities	
Redemptions payable	52,674.41
Provisions for accrued expenses	223,576.65
	276,251.06
Net assets	77,383,722.86

Fund Evolution		31.03.2016	30.09.2015	30.09.2014
Total net assets	USD	77,383,722.86	83,825,029.08	99,035,789.19
Net asset value per share				
B -Capitalisation	USD	126.18	116.31	127.19
EB -Capitalisation	USD	951.26	872.17	943.72
IB -Capitalisation	USD	136.22	125.11	135.84
UB -Capitalisation	USD	99.11	91.01	/
BH -Capitalisation	EUR	103.12	95.55	105.05
IBH -Capitalisation	EUR	985.48	909.22	991.27
UBH -Capitalisation	EUR	98.29	90.66	/

Number of shares outstanding		at the end of the period	at the beginning of the period	Number of shares issued	Number of shares redeemed
B -Capitalisation	USD	328,087.219	360,864.086	77,964.732	110,741.599
EB -Capitalisation	USD	133.157	10.000	133.157	10.000
IB -Capitalisation	USD	133,052.117	194,978.408	4,377.419	66,303.710
UB -Capitalisation	USD	10,954.777	6,044.964	5,008.611	98.798
BH -Capitalisation	EUR	136,912.840	156,630.828	85,075.151	104,793.139
IBH -Capitalisation	EUR	57.581	65.242	2.648	10.309
UBH -Capitalisation	EUR	4,437.220	1,267.831	3,169.389	0.000

Statement of Operations / Changes in Net Assets in USD

For the period from 01.10.2015 to 31.03.2016

Net assets at the beginning of the period	83,825,029.08
Income	
Dividends (net)	935,613.67
Securities lending income	10,114.74
	945,728.41
Expenses	
Management fee	745,004.69
Custodian and safe custody fees	19,385.32
Administration expenses	43,062.04
Printing and publication expenses	13,454.71
Interest and bank charges	1,630.65
Audit, control, legal, representative bank and other expenses	70,889.49
"Taxe d'abonnement"	21,124.61
	914,551.51
Net income (loss)	31,176.90
Realised gain (loss)	
Net realised gain (loss) on sales of investments	-1,759,640.73
Net realised gain (loss) on forward foreign exchange contracts	-1,023,267.93
Net realised gain (loss) on foreign exchange	50,814.78
	-2,732,093.88
Net realised gain (loss)	-2,700,916.98
Change in net unrealised appreciation (depreciation)	
Change in net unrealised appreciation (depreciation) on investments	6,860,493.64
Change in net unrealised appreciation (depreciation) on forward foreign exchange contracts	634,074.84
	7,494,568.48
Net increase (decrease) in net assets as a result of operations	4,793,651.50
Subscriptions / Redemptions	
Subscriptions	20,940,192.50
Redemptions	-32,175,150.22
	-11,234,957.72
Net assets at the end of the period	77,383,722.86
	,000,1 ==100

0.93

0.91

0.67

0.60

97.86

Breakdown by Country 58.18 USA Italy 6.50 United Kingdom 5.60 Australia 5.29 3.55 France 2.72 Spain 2.52 Switzerland New Zealand 2.29 Thailand 2.28 2.12 Canada 1.93 Japan Mexico 1.77

Breakdown by Economic Sector

People's Republic of China

Hong Kong

Germany

Turkey

Total

Energy and water supply	42.97
Traffic and transportation	20.88
Petroleum	12.22
Real estate	9.36
Financial, investment and other div. companies	6.80
Building materials and building industry	2.59
Aeronautic and astronautic industry	2.28
Mechanical engineering and industrial equipment	0.48
Graphics publishing and printing media	0.28
Total	97.86

Statement of Investments in Securities and Other Net Assets

	Description	Quantity / Nominal	Valuation (in USD)	% of net assets
Secu	rities listed on a stock exchange or other organised	I markets: Share	es (and equity-type	securities)
Share	es (and equity-type securities)			
EUR	AENA	7,224.00	933,932.79	1.21
EUR	AEROPORTS DE PARIS	14,000.00	1,733,369.51	2.24
THB	AIRPORTS OF THAILAND PUBLIC COMPANY NVDR	154,200.00	1,762,036.09	2.28
USD	AMERICAN ELECTRIC POWER	31,800.00	2,111,520.00	2.73
USD	AMERICAN TOWER	29,700.00	3,040,389.00	3.93
USD	AMERICAN WATER WORKS	50,300.00	3,467,179.00	4.48
USD	AQUA AMERICA	71,325.00	2,269,561.50	2.93
EUR	ATLANTIA	78,384.00	2,176,789.01	2.81
USD	ATMOS ENERGY	48,700.00	3,616,462.00	4.67
NZD	AUCKLAND INTERNATIONAL AIRPORT	397,500.00	1,774,571.58	2.29
USD	BEIJING CAPITAL INTERNATIONAL AIRPORT -H- CALIFORNIA WATER SERVICE GROUP	672,000.00 14,200.00	717,352.01 379,424.00	0.93 0.49
USD	CHENIERE ENERGY	100,000.00	3,383,000.00	4.37
USD	CROWN CASTLE REIT	48,600.00	4,203,900.00	5.43
USD	DOMINION RESOURCES	11,300.00	848,856.00	1.10
JPY	EAST JAPAN RAILWAY	17,300.00	1,495,038.60	1.93
EUR	EIFFAGE	13,200.00	1,015,339.05	1.31
USD	EVERSOURCE ENERGY	23,600.00	1,376,824.00	1.78
EUR	FERROVIAL	18,000.00	387,367.23	0.50
USD	FIRST SOLAR	5,400.00	369,738.00	0.48
CHF	FLUGHAFEN ZUERICH	2,169.00	1,950,166.82	2.52
EUR	FRAPORT	8,562.00	520,136.45	0.67
FUR	GAS NATURAL GDF SUEZ (strip wpr)	38,656.00 573.00	782,776.40 0.65	1.01
USD	GRUPO AEROPORTUARIO DEL SURESTE -B- ADR	6,600.00	991,122.00	1.28
USD	GRUPO AEROPUERTO DEL PACIFICO ADR S B-	4,300.00	381,453.00	0.49
HKD	GUANGDONG INVESTMENT	558,037.00	705,772.47	0.91
USD	KINDER MORGAN	220,100.00	3,930,986.00	5.08
USD	LACLEDE GROUP	31,700.00	2,147,675.00	2.78
GBP	NATIONAL GRID	136,700.00	1,939,616.86	2.51
USD	NEXTERA ENERGY NISOURCE	11,600.00	1,372,744.00	1.77 3.22
USD	NORTHWESTERN	105,700.00 22,600.00	2,490,292.00 1,395,550.00	1.80
USD	ONE GAS	8,200.00	501,020.00	0.65
USD	ONEOK (new)	29,200.00	871,912.00	1.13
CAD	PEMBINA PIPELINE	31,200.00	846,907.65	1.09
USD	PG&E	32,500.00	1,940,900.00	2.51
EUR	RAI WAY	40,000.00	215,147.04	0.28
USD	SEMPRA ENERGY	9,100.00	946,855.00	1.22
GBP	SEVERN TRENT	37,245.00	1,163,241.78	1.50
USD	SJW	9,000.00	327,150.00	0.42
EUR	SNAM	286,175.00	1,795,239.53	2.32
USD	SOUTHWEST GAS	24,900.00	1,639,665.00	2.12
USD	SPECTRA ENERGY SYDNEY AIRPORT (stapled security)	49,800.00 486,000.00	1,523,880.00 2,501,056.09	1.97 3.23
TRY	TAV HAVALIMALARI HOLDING	77,500.00		0.60
EUR	TERNA	148,000.00	462,679.71 845,796.80	1.09
CAD	TRANSCANADA	20,100.00	793,464.50	1.03
AUD	TRANSURBAN GROUP	182,489.00	1,593,285.48	2.06
GBP	UNITED UTILITIES GROUP	92,492.00	1,227,010.16	1.59
USD	WILLIAMS COMPANIES	53,700.00	862,959.00	1.12
Share	es (and equity-type securities) rities listed on a stock exchange or other organised	markets:	75,729,110.76	97.86
	es (and equity-type securities)		75,729,110.76	97.86
	of Portfolio		75,729,110.76	97.86
	at banks and at brokers		1,452,877.18	1.88
	net assets		201,734.92	0.26
Fotal	net assets		77,383,722.86	100.00

Technical Data and Notes

Technical Data

		Valoren	ISIN	Management Fee	Total Expense Ratio
B -Capitalisation	USD	3786520	LU0348403774	1.92%	2.34%
EB -Capitalisation	USD	22196068	LU0965490591	1.10%	1.45%
IB -Capitalisation	USD	3786523	LU0348403857	1.20%	1.58%
UB -Capitalisation	USD	26412785	LU1144415038	1.15%	1.56%
BH -Capitalisation	EUR	3786535	LU0348404079	1.92%	2.34%
UBH -Capitalisation	EUR	26380945	LU1144415202	1.15%	1.54%
B -Capitalisation	RUB	3786540	LU0348404236	1.92%	2.35%

Fund Performance

		YTD	Since Inception	2015	2014	2013
B -Capitalisation	USD	6.87%	/	5.40%	-46.98%	9.74%
EB -Capitalisation	USD	7.08%	/	6.31%	-46.53%	/
IB -Capitalisation	USD	7.06%	/	6.19%	-46.56%	10.68%
UB -Capitalisation	USD	7.08%	17.63%	/	/	/
BH -Capitalisation	EUR	6.66%	/	4.88%	-47.03%	8.82%
UBH -Capitalisation	EUR	6.87%	16.64%	/	/	/
B -Capitalisation	RUB	-2.14%	/	28.29%	-3.17%	18.03%

Notes

Forward foreign exchange contracts

Purchases		Sales		Maturity	Valuation
Counterparty					(in USD)
EUR	1,094,669.58	USD	-1,220,552.20	15.06.2016	29,885.58
Credit Suisse Zürich					
EUR	41,827.12	USD	-47,400.38	15.06.2016	378.61
Credit Suisse Zürich					
USD	29,182.17	EUR	-25,980.90	15.06.2016	-494.55
Credit Suisse Zürich					
EUR	16,553.39	USD	-18,918.89	15.06.2016	-10.00
Credit Suisse Zürich					
Net unrealised gain	on forward foreign e	xchange contracts			29,759.64

Statement of Net Assets in USD and Fund Evolution

	31.03.2016
Assets	
Investments in securities at market value	58,431,746.06
Cash at banks and at brokers	647,769.85
Subscriptions receivable	1,329.91
Income receivable	304.65
Net unrealised gain on forward foreign exchange contracts	29,759.64
	59,110,910.11
Liabilities	
Redemptions payable	36,281.60
Provisions for accrued expenses	97,242.54
Other liabilities	0.62
	133,524.76
Net assets	58,977,385.35

Fund Evolution		31.03.2016	30.09.2015	30.09.2014
Total net assets	USD	58,977,385.35	62,659,290.09	106,627,926.55
Net asset value per share				
B -Capitalisation	USD	90.06	83.30	117.40
EB -Capitalisation	USD	61.69	56.83	79.40
IB -Capitalisation	USD	96.02	88.50	123.75
UB -Capitalisation	USD	117.63	108.39	/
BH -Capitalisation	EUR	78.92	73.16	103.39
UBH -Capitalisation	EUR	116.64	107.71	/
B -Capitalisation	RUB	1,729.03	1,569.12	1,333.06

Number of shares outstanding		at the end of the period	at the beginning of the period	Number of shares issued	Number of shares redeemed
B -Capitalisation	USD	486,013.070	529,787.114	20,476.839	64,250.883
EB -Capitalisation	USD	189,793.181	265,890.358	28,304.231	104,401.408
IB -Capitalisation	USD	6,642.631	6,642.631	6,334.934	6,334.934
UB -Capitalisation	USD	7,139.939	3,315.176	4,993.490	1,168.727
BH -Capitalisation	EUR	9,199.243	9,113.378	2,836.564	2,750.699
UBH -Capitalisation	EUR	3,598.850	98.850	3,500.000	0.000
B -Capitalisation	RUB	18,998.058	71,620.000	3,988.058	56,610.000

Statement of Operations / Changes in Net Assets in USD

For the period from 01.10.2015 to 31.03.2016

Net assets at the beginning of the period	62,659,290.09
Income	
Dividends (net)	558,816.68
Securities lending income	30,417.45
	589,234.13
Expenses	
Management fee	518,749.47
Custodian and safe custody fees	13,516.65
Administration expenses	26,199.24
Printing and publication expenses	10,217.22
Interest and bank charges	183.73
Audit, control, legal, representative bank and other expenses	45,642.29
"Taxe d'abonnement"	12,463.35
	626,971.95
Net income (loss)	-37,737.82
Realised gain (loss)	
Net realised gain (loss) on sales of investments	-10,229,060.86
Net realised gain (loss) on forward foreign exchange contracts	-19,169.74
Net realised gain (loss) on foreign exchange	-8,524.68
	-10,256,755.28
Net realised gain (loss)	-10,294,493.10
Change in net unrealised appreciation (depreciation)	
Change in net unrealised appreciation (depreciation) on investments	14,657,972.47
Change in net unrealised appreciation (depreciation) on forward foreign exchange contracts	41,057.55
Change in the direction appreciation (depreciation) on formal direction and contracts	14,699,030.02
Net increase (decrease) in net accete as a result of anarotions	4,404,536.92
Net increase (decrease) in net assets as a result of operations	4,404,530.52
Subscriptions / Redemptions	
Subscriptions	5,359,282.81
Redemptions	-13,445,724.47
	-8,086,441.66
Net assets at the end of the period	58,977,385.35

Breakdown by Country

Total	99.07
USA	2.32
Cyprus	4.30
Virgin Islands (UK)	10.14
Netherlands	12.55
Russia	69.76

Breakdown by Economic Sector

Petroleum	17.49
Internet, software and IT services	14.40
Financial, investment and other div. companies	12.23
Food and soft drinks	9.61
Banks and other credit institutions	8.63
Retailing, department stores	7.35
Telecommunication	6.16
Mining, coal and steel industry	4.79
Building materials and building industry	4.04
Chemicals	3.46
Non-ferrous metals	3.43
Miscellaneous services	3.24
Electrical appliances and components	2.02
Traffic and transportation	1.89
Mechanical engineering and industrial equipment	0.33
Total	99.07

Statement of Investments in Securities and Other Net Assets

	Description	Quantity / Nominal	Valuation (in USD)	% of net assets
Secu	rities listed on a stock exchange or other organia	sed markets: Share	s (and equity-type	securities)
Share	es (and equity-type securities)			
USD	AEROFLOT	1,000,000.00	1,113,969.00	1.89
USD	ALROSA	1,961,000.00	2,041,363.74	3.46
USD	BASHNEFT	29,009.00	1,132,417.78	1.92
USD	DIXY GROUP	224,610.00	1,016,220.32	1.72
USD	EPAM SYSTEMS	18,200.00	1,358,994.00	2.30
USD	GAZPROM OAO (reg. shares) -S- ADR	416,000.00	1,794,208.00	3.04
USD	GLOBALTRANS INVESTMENT (regS-) GDR	586,433.00	2,536,322.73	4.30
USD	GROUP LSR GDR (regS-)	1,047,597.00	2,383,283.18	4.04
USD	JSFC SISTEMA (reg. shares) -S- GDR	54,500.00	352,070.00	0.60
USD	LENTA (reg. shares) GDR	303,944.00	1,911,807.76	3.24
USD	LUKOIL ADR	79,800.00	3,065,517.00	5.20
USD	LUXOFT HOLDING	44,313.00	2,438,544.39	4.13
USD	M VIDEO COMPANY	298,310.00	1,188,599.19	2.02
USD	MAGNIT	29,460.00	4,648,561.89	7.89
USD	MAIL.RU GROUP (regS-) GDR	75,355.00	1,635,203.50	2.77
USD	MEFAFON (reg. shares) GDR	44,654.00	491,194.00	0.83
USD	MMC NORILSK NICKEL PJSC adr	156,902.00	2,025,604.82	3.43
USD	MOBILE TELESYSTEMS	776,350.00	2,787,938.06	4.73
USD	MOSCOW EXCHANGE MICEX	1,411,256.00	2,217,355.55	3.76
USD	NOVATEK GDR	27,234.00	2,446,974.90	4.15
USD	NOVOLIPETSK STEEL (reg. shares) GDR	134,117.00	1,676,462.50	2.84
USD	QIWI ADR -B-	926.00	13,417.74	0.02
USD	ROSNEFT OIL COMPANY	107,500.00	488,265.00	0.83
USD	ROSNEFT OIL COMPANY (reg. shares) GDR	378,000.00	1,716,876.00	2.91
USD	SBERBANK OF RUSSIA	3,094,100.00	5,085,871.18	8.63
USD	SEVERSTAL GDR (regS-) S. OCT06	108,500.00	1,147,930.00	1.95
USD	TATNEFT GDR	66,552.00	2,119,015.68	3.59
USD	TRUBNAYA METALLURGICHESKAYA KOMPANYA (reg. shares) ADR	63,745.00	193,147.35	0.33
USD	X 5 RETAIL GROUP	204,529.00	4,336,014.80	7.35
USD	YANDEX -A-	200,300.00	3,068,596.00	5.20
	es (and equity-type securities) rities listed on a stock exchange or other organi	and marketer	58,431,746.06	99.07
	es (and equity-type securities)	sed markets:	58,431,746.06	99.07
Total	of Portfolio		58,431,746.06	99.07
Cash	at banks and at brokers		647,769.85	1.10
Other net liabilities		-102,130.56	-0.17	
Total	net assets		58,977,385.35	100.00



CS Investment Funds 5 5, rue Jean Monnet L-2180 Luxembourg www.credit-suisse.com